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ABSTRACT

Endogenous opioids are known to modify LH and GH secretion through the hypothalamo-
pituitary axis. This study aimed at verifying the direct action of opioids on LH and GH
secretion at the pituitary level using pituitaries (adenohypophyses) of pigs in a perifusion in
vitro system. Furthermore to determine whether opioidergic modulated release of LH and GH
is altered by LHRH or GHRH stimulation at the pituitary in pigs and if these effects are sex-,
and age-dependent.
ß-endorphin (5*10-9M) significantly increased the release of LH in fetuses (425% in males
and 275% in females) piglets (325% in males and  175% in females) adults (245% in males
and 160% in females with high (P>3.5ng/ml) progesterone concentration) as compared to
saline controls. Naloxone (10-6M) and dalargin (10-6M) showed no effects. Surprisingly
naloxone did not antagonise the ß-endorphin-induced LH release when concomitantly
administered to pituitaries of adult females and males. Pretreatment with ß-endorphin
attenuated LHRH-stimulated LH release in fetal and adult females but not males, leaving
piglets unaffected. Naloxone and dalargin impaired LHRH-induced LH increment in both
adults and fetuses. Again naloxone and dalargin preadministration had no influence on
LHRH-induced LH release in piglets.
The opiate agonists, ß-endorphin and dalargin caused a significant increase in GH secretion
in pituitaries of adult males but not in females thus indicating a sex-differential effect.
Whereas naloxone showed no effect in both sexes, concomitant administration of ß-
endorphin and naloxone showed antagonism in adult males but not in females. In piglets,
naloxone elicited an increase in GH secretion in females whereas in males, a non-significant
decrease was observed. ß-endorphin and dalargin showed no effects in pituitaries of both
female and male of piglets. On the otherhand, ß-endorphin increased GH secretion
significantly in pituitaries of fetal males but not in females. Dalargin and naloxone showed no
effects in both female and male fetuses unlike in adults and piglets.
Pretreatment with ß-endorphin tended to potentiate GHRH-stimulated GH release from
pituitaries of adult males. Interestingly, posttreatment with LHRH diminished GH discharge
in adult females pretreated with ß-endorphin and naloxone leaving males unaffected.
These findings indicate that effects of  opioids on spontaneous LH and GH secretion are
evident in the pig pituitary and these effects are sex-, age- and steriod-dependent. Opioids
could play a major role in modifying LHRH-induced LH release but exert minor effects in
modulating GHRH-induced GH discharge from the pig pituitary.   

Key words : OPIOIDS, HORMONES , PIG

ABSTRACT
      
Endogene Opioide modulieren die Sekretion von LH und GH hauptsächlich über die Hypothalamus-
Hypophysenachse . Im Rahmen dieser Arbeit sollte der Einfluß von Opioiden auf die LH und GH
Sekretion auf der hypophysären Ebene in einem Superfusionssystem untersucht werden. Weiterhin
wurde untersucht, ob Opioide die LHRH induzierte LH-Ausschüttung bzw. GH Sekretion
beeinflussen und ob die Effekte Alters-, und Geschlechtsabhängig sind.
Aus den Ergebnissen geht hervor, dass ß-Endorphin (5*10-9) einen signifikanten Anstieg der
hypophysären LH Sekretion in Föten (425% bei männlichen vs 275% bei weiblichen), bei Ferkeln
(325% bei männlichen vs 175% bei weiblichen) und bei Adulten (245% bei männlichen vs 160% bei
weiblichen, mit einer höheren Progesteron Konzentration=P>3.5ng/ml) verursachte. Naloxon (10-6M)
und Dalargin (10-6M) dagegen wiesen keine Effekte auf. Die Vorbehandlung mit ß-Endorphin führte
zu Blockaden der LHRH-stimulierende LH-Ausschüttung sowohl bei fötalen als auch bei adulten
weiblichen aber nicht bei männlichen Hypophysen, während die Reaktion der Ferkel unverändert
blieb. Anderseits haben Naloxon und Dalargin die LHRH induzierte LH- Ausschüttung bei adulten
und fötalen Hypophysen nur leicht verdrängt. Die Vorbehandlung mit Naloxon und Dalargin zeigte
dagegen keinen Effekt bei Ferkeln.
Die Opioid-Agonisten, ß-Endorphin und Dalargin verursachten einen signifikanten Anstieg
der GH Sekretion bei Eber aber nicht bei Sauen. Dies deutet einen geschlechtsdifferenzierten Effekt
an, wogegen Naloxon keinen Effekt bei beiden Geschlechten aufwies. Naloxon zeigte einen
Antagonismus mit ß-Endorphin bei männlichen aber nicht bei weiblichen adulten Hypophysen. Bei
den Ferkeln führte Naloxon zu einem Anstieg der GH Sekretion bei weiblichen, während  bei
männlichen nur eine nicht-signifikante Verringerung der GH Sekretion beobachtet wurde. ß-
Endorphin und Dalargin wiesen keine Effekte bei männlichen und weiblichen Ferkeln auf. ß-
Endorphin führte zu einem signifikanten GH Anstieg bei männlichen fötalen Hypophysen, nicht
jedoch bei weiblichen. Dalargin und Naloxon dagegen zeigten keinen Effekt auf die GH Sekretion
bei weiblichen und männlichen fötalen Hypophysen. Die Vorbehandlung mit ß-Endorphin hatte keine
signifikante Wirkung auf die GHRH-induzierte GH Ausschüttung. Lediglich war eine relativ starke
aber nicht signifikante Potenzierung der GHRH-induzierte GH Sekretion bei Ebern zu beobachten.
Die Behandlung mit LHRH führte zu einer Verringerung der GH Ausschüttung bei weiblichen
Hypophysen, aber nicht bei männlichen, die zuvor mit ß-Endorphin und Naloxon behandelt wurden.
Aus diesen Ergebnissen geht hervor, daß Opioide die spontane LH und GH Sekretion auf der
hypophysären Ebene modulieren. Diese Effekte sind von Geschlecht, Alter und gonadalen Steriode
abhängig. Opioide können eine bedeutende Rolle bei der Modulation der LHRH-induzierten LH
Ausschüttung spielen, aber sie zeigen einen geringen Effekt bei der Modulation der GHRH-
induzierten GH Sekretion der Schweinhypophysen.
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1.0 INTRODUCTION

One of the systems modulating physiological events in the body is the opioid system.
According to investigations carried out in the recent decades, opioids are presumed to
play a vital role in the control of reproductive activity, growth and behaviour in farm
animals and other species (Rahe et al., 1980, Parvizi et al., 1993, Schouten and
Rushen, 1993). The effects of opioids on the secretion of different hormones are sex-,
age-dependent and vary slightly in different species. Opioid modulation of
gonadotrophic and somatotrophic hormone secretion also depends on intrinsic factors
like the steriod hormone concentration and extrinsic factors including stress,
photoperiod and seasonality. The interaction of the opioidergic system and the
immunological system has recently been established. Interleukine-1ß has been shown
to stimulate opioid production that is presumed to be highly functional during stress
situations in cells or tissues. Available evidence suggest that endogenous opioids and
their receptors comprise one of the systems that translates ovarian hormone signals
into changes in LHRH and LH release. The endogenous opioid receptors have been
identified, characterised and are located in different parts of the body including the
brain, spinal cord, pituitary, hypothalamus, ileum, adrenal medulla, blood cells, etc.
Experimental studies have also recorded that the hormonal changes in response to the
opioids depend on the route of opioid administration. It was observed that actions
through subcutaneous (s.c.), intramuscular (i.m.), intravenous (i.v.),
intracerebroventricular (i.c.v.) were increasing in effectiveness respectively. The
majority of experimental data reported has led to the general assumption that
endogenous opioid modulation of luteinizing hormone release and growth hormone
secretion is achieved predominantly through  the hypothalamic-pituitary-axis.
However direct effects on  the pituitary are feasible. The feasibility of the direct
effects of opioids at the pituitary level implies that the opioid actions are not
necessarily brought about by changing the LHRH or GRF and /or Somatostatin imput.
But could also act by changing the pituitary response to LHRH  to alter LH secretion
or GRF and/ or Somatostatin to influence GH release.
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1.1  Literature Review

Opiates, denoted from the alkaloids of opium and its derivatives are amongst the
oldest drugs or analgesics with morphine-like effects used in medicine. According to
Theophrastus the use of opiates began in the year 300 BC.The probability of the
existence of receptors for these opiates was first theorised by Beckett and Casy
(1954). Thereafter there was increasing interest in the identification, classification and
isolation of these opiate receptors by different researchers. In 1973 came the discovery
of the opiate binding sites in homogenates of the brains of different mammals through
opiate ligand binding assays (Pert and Synder,1973; Simon et al.,1973; Terennius,
1973; Wong and Horng,1973). Two years later it was discovered that there existed
endogenous opiate peptides or ligands that bound to these receptors (Hughes et
al.,1975). The isolation of two pentapeptides Leucine (Leu)-Enkephaline and
Methionine (Met)-Enkephaline with morphine-like activity from  pig brain marked
the beginning of the opioid era (Hughes, 1975). In the same year, a long chain peptide
was extracted from the pituitary of cow that showed morphine like activity. Another
endogenous peptide, ß-endorphin, with morphine like activity was isolated and the
amino acid chain of 31 amino acid  residues was established (Cox et al., 1975 ; Li and
Chung, 1976). Later on many other endogenous opioids were identified and their
amino acid sequence determined as seen on table 1 (Nakanishi et al., 1979; Kakidani
et al., 1982, Meunier et al., 1995).

1.2       Classification and characterization of endogenous opioids  and their                                                    
    receptors

The term "opiate" was originally designated to narcotic drugs derived from opium, ie
morphine, codeine, and many semisynthetic derivatives. Later, the word "opioid" was
coined to refer in a generic sense to all drugs, natural and synthetic, which have
morphine-related actions, as well as to the endogenous peptides later discovered with
such actions. However many authors interchange these terms.
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There are approximately 15 naturally occuring endopeptides with opiate activity
called endogenous opioids. These endogenous opioids are derived from the three
classical precursor proteins : proopiomelanocortin (POMC) , proenkephalin
(PROENK), prodynorphin (PRODYN) and two recently discovered neuropeptide
families : orphanin FQ /nociceptin and endomorphin-1 (EM-1) and endomorphin-2
(EM-2) which are derived from the precursor peptides pro-nociceptin/ orphanin FQ
and pro-endomorphin (yet-to-be discovered) respectively.

The three classical families give rise to three classes of opioids namely: endorphins,
enkephalins and  dynorphins respectively (Noda et al.,1982; Gubler et al., 1982 ;
Kakidani et al., 1982). These three families of opioids are believed to originate from a
common phylogenetic gene because their precursors possess almost the same number
of amino acid residues (approx. 240 a.a ; scheme 1) and the opioid primers being
located at the C-terminal while the N-terminal shows a homologous chain of amino
acid sequence (Simon, 1991).  The N-terminals of the opioids derived from these three
precursor  proteins possess as  amino acid sequence at positions 1- 4 : Tyr - Gly - Gly
- Phe (see table 1). The difference in the various derivatives lies on the remaining
amino acid sequence that constitute the C-terminal of the chain. The length of the C-
terminal determines the half life of these different opioids (Hughes, 1983) and also
seems to dictate the receptor selectivity (Höllt, 1986; Goldstein & Naidu, 1989).

The cloning of the POMC-mRNA from bovine cDNA revealed that POMC was a long
polypeptide made up of 241 amino acids that contained ; N-terminal peptide (103a.a.),
ß-LPH (93 a.a.) and ACTH (39 a.a.) with many derivatives amongst which the
endogenous opioid ß-endorphin was identified (Nakanishi et al., 1979). 
Although ß-endorphin contains the sequence of met-enkephalin, it has not yet been
proven that this endogenous opioid could be synthesized from POMC.  ß-endorphin
(1-31) binds to µ and δ  receptors with almost the same affinity (Kosterlitz et al., 1986;
Akil et al., 1988).
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The shortening of the amino acid chain of ß-endorphin reduces its affinity to its µ- and
δ-receptors (Akil et al., 1981 and Ferrara & Li, 1982). On the otherhand, opioids with
different intrinsic activities could arise whereby ß-endorphin (1-31) is a potent
agonist, whereas ß-endorphin (1-27) a potent antagonist of opioids (Nicholas & Li,
1985). The acetylated N-terminal of the endorphins binds relatively weakly to the
opioid receptor and therefore shows no opioid activity (Akil et al., 1988).

It is worthmentioning that the structure of the POMC-gene in the mouse unlike  other
animal species occasionally expresses pseudogenicity that results from an anomalie in
the original gene. This pseudogene exhibits a 92% homology to the functional gene
but two codons are not fully expressed. ß-endorphin and other derivatives like ACTH
(which are cleaved by trypsin-like endopeptidases) cannot be synthesized from  this
pseudogene (Friedemann, 1994).

ß-endorphin was postulated to bind to another endogenous opioid receptor called
epsilon "ε" (Wüster et al., 1979) but this suggestion was rejected later (Goldstein &
Naidu, 1989 and Pleuvry, 1991).

Proenkephalin, precursor peptide for the enkephalins is made up of 239 a.a. and it
possesses opioid derivatives as shown on scheme 1. The enkephalins (ENK) generally
have a high affinity to δ-receptors (Akil et al., 1988; Pleuvry, 1991 and Simon 1991).
However metorphamid and BAM-18 show high affinities for µ and κ receptors
(Corbett et al., 1982, Magnan et al., 1982, Hurblut et al., 1987).

The precursor protein, prodynorphin was cloned and sequenced from porcine
adenohypophysis and contains 236 a.a (Kakidani et al., 1982). It contains dynorphin
(DYN) and other opioid derivatives which show high affinity for κ-receptors
(Chavkin et al., 1982; Corbett et al., 1982; Young et al., 1986).  DYN (1-8) is highly
selective for µ and δ-receptors.
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  PROOPIOMELANOCORTIN (POMC): 241 AA  (Porcine)

 NH2                                      COOH
 
             
        γ-MSH α-MSH  CLIP             β-MSH α-END
          γ3-MSH          
         γ-END
         
         β-END(1-27)
           
   16k-Fragment    γ-LPH      β-END(1-31)
                
      ACTH  β-LPH


PROENKEPHALIN (PROENK) : 239 AA (Bovine)

 NH2                      COOH
      

BAM-12P
BAM- 18P
BAM- 20P
    Amidorphin  BAM-22P
 
        
    Peptide F MERGL  Peptide E   MERF
       
       Metorphamid

  PRODYNORPHIN (PRODYN)  236 AA (Porcine)
     
NH2           COOH
      
 
            β-NE      DYN(1-8)
            
     α-NEDYNN A
  
  DYN(1-24)
  
  DYN B
  
  DYN(1-32)
  
  Leumorphin


MET-Enkephalin : TRY-GLY-GLY-PHE-MET

                    LEU- Enkephalin  :


TRY-GLY-GLY-PHE-LEU

Scheme 1 :  Schematic representation of the primary structures of the three precursor genes for
the three largest opioid families and some of their opioid derivatives.
After Cox (1982), Schulz and Ehrenreich (1985) as modified by Kahle (1993). 
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Amongst the lately discovered endogenous opioid families is the novel
heptadecapeptide, Orphanin FQ (Nociceptin) which was identified and purified from
porcine brain tissue (Meunier et al., 1995). This opioid was identified as a ligand for
an earlier isolated orphan heterotrimeric GTP-binding protein (G-protein)-coupled
receptor called opioid receptor-like-1(ORL1), that is structurally and functionally
similar to opioid receptors (Mollereau et al., 1994).
 Nociceptin has a primary structure reminiscent of that of opioid peptides and is said
 to be processed from the precursor protein Pro-nociceptin/ OFQ (Meunier et al.,
1995). Orphanin FQ binds to its receptor, opioid receptor like-1 (ORL1) with high
affinity and is widely distributed in different brain regions in the guinea pig (Sinn and
Childer, 1997). When injected intracerebroventricularly into mice, Orphanin FQ
caused a decrease in locomotor activity but did not induce analgesia in the hot-plate
test. However, application of nociceptin produced hyperanalgesia in the tail-flick
assay. Thus, Orphanin FQ may act as a transmitter in the brain by modulating
nociceptive and locomotor behaviour (Reinscheid, 1995). A novel synthetic peptide,
[Nphe (1) nociceptin (1-13) NH (2)]  has been introduced as the true selective and
competitive nociceptin receptor antagonist which is devoid of any residual agonist
activity (Calo’ et al., 2000).

Recently two other peptides have been isolated from bovine brain that have high
affinity and selectivity for the mu-opioid receptor and have been termed:
endomorphin-1 (Tyr-Pro-Trp-Phe-NH2 ) and endomorphin-2 (Tyr-Pro-Phe-Phe- NH2).
The new class of endogenous opioids are presumed to be derived from the yet-to-be
discovered precursor protein pro-endomorphin (Zadina et al., 1997).

Tonini et al., (1998) revealed that the novel opioid tetrapeptides, Endomorphin-1 and
Endomorphin-2 show selectivity for mu-opioid receptors located on excitatory
myenteric plexus neurones in guinea pig and that they act as full agonists. The mu-
opioid receptor selective peptide, endomorphin-1 has been reported to stimulate
oxygen consumption in mice. This effect could be blocked by naloxone (Asakawa et
al., 2000).
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Endomorphin-2 based on its distribution in the CNS, could play a role in the control
of neuroendocrine, cardiovascular, respiratory function, mood, sexual behaviour and
pain in the rat (Pierce and Wesendorf, 2000).

Apart from the endogenous opioid peptides and derivatives from the above-mentioned
precursor proteins, there exist a number of endogenous and exogenous peptides with
opioid activity, whose physiological roles are not yet fully established. These include;
Dermorphin, isolated from amphibian skin (Montecucchi et al., 1981) which is a
potent µ-receptor agonist. Kreil et al., (1989) presented another endogenous peptide
called Deltorphin with opioid activity. [D-Ala²]- Deltorphin I and [D-Ala²]-Deltorphin
II (Erspamer et al., 1989) which has a high affinity for the δ-receptor.

The endogenous opioid, Kyotorphin, a dipeptide isolated from bovine brain extracts
(Takagi et al., 1979), Humoral endorphin (H-endorphin), the α and β-casomorphin
extracted from milk of different animal species (Henschen et al., 1979, Loukas et al.,
1983; Ramabadran and Bansinath, 1989; Hazum,1991). Morphiceptin, a synthetic
tetrapeptide with high affinity for the µ-receptor constitutes part of  the N-terminal of
β-casomorphin (1-11) as presumed by Chang et al.(1981), James and Goldstein (1984)
which is perhaps a natural constituent of milk (Hazum,1991). Anodymin, is another
endogenous opioid  in the blood and brain, further reading is directed to Kitchen
(1984) and Martinez (1989).
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Table 1: The amino acid sequence for endogenous opioids and their derivatives.


Name of Opioid

Other names

         Amino acid sequence

Pre-proopiomelanocortin:       Pre-POMC ß-LPH (61-91)

ß-Endorphin C-Fragment, ß-LPH (61-91)     61Tyr-Gly-Gly-Phe-Met-Thr-Ser-

C-Fragment ß-LPH(61-87),δ-Endorphin Glu-Lys-Ser-Gln-Thr-Pro-Leu-
Val
γ-Endorphin                            ß-LPH (61-77) 76Thr-77Leu-Phe-Lys-Asn-Ala-
 
α-Endorphin                           ß-LPH (61-76) Ile-Val-Lys-Asn-Ala-87His-Lys-
Lys-Gly-91Gln

Pre-proenkephalin: Pre-proenkephalin A
Met-Enkephalin                      Methionin-Enkephalin Try-Gly-Gly-Phe-Met
Met-Enkephalyl-Arg 6                 Pro-Methionin-Enkephalin Try-Gly-Gly-Phe-Met-Arg
Met-Enkephalyl-Lys  6                 Met-enkephalin-Lys  6 Try-Gly-Gly-Phe-Met-Lys
Met-Enkephalyl-Arg 6-Phe 7   Met-Enkephalin-Arg-Phe, Try-Gly-Gly-Phe-Met-Arg-Phe
MEAP, MERF
Met-Enkephalyl-Arg 6-Arg 7   Met-Enkephalin-Arg-Arg Tyr-Gly-Gly-Phe-Met-Arg-Arg
Met-Enkephalyl-Arg 6-Gly 7    Met-Enkephalin-Arg-Gly- Tyr-Gly-Gly-Phe-Met-Gly-Leu
-Leu 8 Leu, MERGL

Leu-Enkephalin                      Leucine-Enkephalin Tyr-Gly-Gly-Phe-Leu


Peptide B Phe-Ala-Glu-Pro-Leu-Pro-Ser-
Glu-Glu-Glu-Gly-Glu-Ser-Tyr-
Ser-Lys-Glu-Val-Pro-Glu-Met-
Glu-Lys-Arg-Tyr-Gly-Gly-Phe-
Met-Arg-Phe

Peptide F Tyr-Gly-Gly-Phe-Met-Lys-Lys-
Met-Asp-Glu-Leu-Tyr-Pro-Leu-
Glu-Val-Glu-Glu-Glu-Ala-Asn-
Gly-Gly-Glu-Val-Leu-Gly-Lys-
Arg-Tyr-Gly-Gly-Phe-Met

Peptide I Ser-Pro-Thr-Leu-Glu-Asp-Glu-
His-Lys-Glu-Leu-Gln-Lys-Arg-
15Tyr-Gly-Gly-Phe-Met-Arg-
Arg-Val-Gly-Arg-Pro-26Glu-Trp-
Met-Asp-Tyr-Gln-Lys-34Arg-
Tyr-36Gly-Gly-Phe-39Leu

Peptide E Peptide I (15-39)

BAM-12P                     Bovine Adrenal Medulla Peptide I (15-26)
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BAM-20P Peptide I (15-34)


BAM-22P                                                                               Peptide I (15-36)


Metrophamid                          Adrenorphin Peptide E (1-8) NH2

Synenkephalin                                    Pre-proenkephalin (1-70)


Pre-prodynorphin:  Pre-proenkephalin B

[Leu]Enkephalyl-Arg6               Leu-Enkephalin-Arg6 Tyr-Gly-Gly-Phe-Leu-Arg

ß-Neoendorphin Tyr-Gly-Gly-Phe-Leu-Arg-
LysTyr-Pro

α-Neoendorphin Tyr-Gly-Gly-Phe-Leu-Arg-Tyr-
Pro-Lys

Dynorphin 32 1Tyr-Gly-Gly-Phe-Leu-Arg-Arg-
8Ile-Arg-Pro-Lys-Leu-13Lys-Trp-
Asp-Asn-17Gln-Lys-Arg-20Tyr-
Gly-Gly-Phe-Leu-Arg-Arg-Gln-
Phe-Lys-Val-Val-32Thr

Dynorphin 1-8PH        (Porcine Hypothalamus)-8P      Sequence 1-8 (of Dynorphin32)

Dynorphin A                Dynorphin (1-17) Sequence 1-17

Dynorphin B                Rimorphin Sequence 20-32

Leumorphin Tyr-Gly-Gly-Phe-Leu-Arg-
Arg-Gln-Phe-Lys-Val-Val-
Thr-Arg-Ser-Gln-Glu-Asp-
Pro-Asn-Ala-Tyr-Tyr-Glu-
Glu-Leu-Phe-Asp-Val

Nociceptin                   Orphanin FQ Phe-Gly-Gly-Phe-Thr-Gly-
Ala-Arg-Lys-Ser-Ala-Arg-
Lys-Leu-Ala-Asn-Gln
   
  
Endomorphin-1            EM-1 Tyr-Pro-Trp-Phe-NH2

Endomorphin-2            EM-2 Tyr-Pro-Phe-Phe-NH2
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Other Opioids:   
   
1-) Kyotorphin Try-Gly
2-) Dermorphin                                                               Tyr-D-Ala-Phe-Gly-Tyr-Pro
                                                                                        Ser-NH2
3-) Humoral endorphin             H-Endorphin  
4-) Anodynin
5-) ß-CasomorphinTyr-Pro-Phe-Pro-Gly-Pro-Ile-
NH2
6-) Morphiceptin  Tyr-Phe-Pro-Co-NH2


 The acceptance of these peptides as endogenous opioids is a matter of dispute
(Chiba et al.,1989).
1-) Opioid discovered in Kyoto.
2-) Opioid isolated from the skin of a South-American frog, Deltorphin.
3-) An opioid in blood, cerebrospinalfluid and brain.
4-) Opioid found in blood and in the brain.
5-) An opioid obtained from ß-caesin in milk.
6-) A fraction of the ß-caesin and potent µ-receptor-analog.

Note: On the table above the amino acid (a.a.) sequence of porcine ß-endorphin is
given. In other animal species this sequence is slightly altered e.g In bovine, camel
and ovine ß-endorphin, Val at position 83 is replaced by Ile. Human ß-endorphin
possesses in position 87 and 91 Tyr and Glu respectively (Friedemann,1994; Martin-
Schild et al.,1999; Reinscheid et al., 1995).

As earlier mentioned, Beckett and Casy (1954) suggested the possible existence of a
biochemical substance at the tissue level or enzyme system with complementary
stereochemical configuration of an opiate that mediated it's function in the cell. Yet,
the existence of a single receptor for different opiates was questionable until Martin et
al., (1976) owing to their observation from behavioral and neurophysiological studies
on dogs postulated that there existed three different types of opiate receptors.
Martin et al., (1976) observed that morphine and morphine-like substances interacted
with specific receptors which they denoted as µ (mu)-receptors ; other synthetic
opiates, ketocyclazocine and ethylketocyclazocine interacted with κ (kappa)-
receptors and lastly SKF 10047 (N-allyl-norcyclazocine) interacted with the σ
(sigma)-receptors. The cloning and sequencing of  the opioid receptors (µ-398, δ-372,
κ-380 a.a.) of the rat revealed 60% homogenity in their amino acid chain thus
indicating a close structural and pharmacological relationship to one another (Satoh
and Minami, 1995).
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However, the application of mono and polyclonal antibodies against µ and δ-receptors
revealed that endogenous opioid receptors possess different immunogenetic
characteristics and therefore could represent molecules of separate entities (Carr et
al.,1990).

The isolation of Met-enkephalin and Leu-enkephalin from the vas deferens of the
mouse led to the discovery of the δ  (delta)-receptor that showed very high affinity to
these enkephalins (Hughes et al.,1975; Lord et al., 1977). However, there exist other
receptors binding to different endogenous and exogenous opioid ligands (see table 2).

The opioid receptor ε  (epsilon) showed high affinity for ß-endorphin and the λ
(lambda)-receptor showed high affinity for naloxone and epoxymorphine (Grevel et
al., 1985). The putative epsilon receptor is not a pecularity of rat brain but is readily
measurable in forebrain of guinea pig, cow, chicken and pig brain as well. It is more
abundant than mu, delta or kappa-1 receptor, representing 38 to 55% of the total
opioid population in all species examined (Nock et al.,1993).

Zagon et al.,(1991) named the ζ-(Zeta) receptor after the Greek word for life Zoe and
postulated that the interaction of Met-enkephalin with ζ-receptor provoked growth of
nerve cells.

Numerous studies have revealed that µ, δ  and κ- receptors possess different subtypes.
The existence of these subtypes denoted µ1  and µ2  for µ (Pasternak, 1982 ; Pasternak
and Wood, 1986, Childers, 1993) and κ1 and κ2  for κ (Attali et al., 1982; Zukin et
al.,1988) has been established. Furthermore, Clark et al., (1989) proposed the
existence of a κ3  site, with high affinity to naloxone benzoylhydrazone but no affinity
for U50,488H.

The existence of δ1 and δ2-opioid receptor subtypes has been suggested through
behavioural and binding studies (Portoghese et al.,1992; Armstead, 1995).
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Pharmacological studies of ligands binding to sigma receptors using brain tissue from
the guinea pig revealed two subtypes of sigma receptors designated sigma 1 (σ1) and
sigma (σ2) (Gonzalez and Werling, 1997).

Recently, Schlicker et al., (1998) cloned the opioid receptor-like-1 (ORL-1) that binds
with the lately identified endogenous opioid peptide, nociceptin (orphanin FQ). The
existence of a subtype of this receptor has not yet been established. 

Table 2 : Some common selective synthetic exogenous and endogenous ligands for
different endogenous opioid receptors (Calo’s et al., 2000).


Receptor Type Enogenous Ligand Exogenous (specific) Ligand


µ    ß-endorphin, Enkephalin,           Morphin, Naloxone, DAGO

Dynorphin, Endomorphine 1& 2  BIT, DAMGO, Methadone,
     Etorphine, Buprenorphine

δ  Enkephalin,Endorphin   Morphin, Naloxone, Dalargin
      Buprenorphine,DPDPE, BNTX
SUPERFIT, SNC80, Natrindole

κ    Dynorphin     Morphin, Naloxone, U69593,
       Buprenorphine, nor-binaltorphine
U-50.488H, Ketocyclazocine

ε    ß-endorphin         ?

σ  ?     SKF 10.047, PCP,Buprenorphine
       Dizocilpine

λ   ?     Naloxone, 4,5 Epoxymorphinan

ORL-1      Nociceptin  (OrphaninFQ)                [Phe1psi(CH2-NH)Gly2]NC
       (1-13) NH2
       [Nphe(1) nociceptin (1-13) NH2]
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Having highlighted the different opioid receptors in different animal species, the
development of opioid receptors in the porcine species will be elaborated  hereafter.
In the pig, opioid receptors in the pituitary and CNS are not detectable until day 50
post coitus (p.c). The fetal pig shows a sex-differential expression of opioid receptors
regarding their number and affinity to opioid ligands as fetal development proceeds
until birth (Parvizi, 1988). During gestation the number of binding sites increases
dramatically in female fetuses such that shortly before birth, the number is almost
twice as much as that of male fetuses (Parvizi, 1988). However at the end of
pregnancy, receptors of the male fetuses show a higher affinity to their endogenous
ligands than the females (Parvizi, 1988). Amongst the endogenous opioid receptors µ
and κ  are predominant during the fetal stage whereas the δ is virtually absent (Kahle
and Parvizi, 1993; Parvizi et al., 1995).

Around puberty females have less binding sites than males in the striatum and
hippocampus. But in adult animals, the females have significantly more binding sites
in the hypothalamus and amygdala than the males. In cyclic females it was also
suggested that opioid binding sites do not fluctuate during the oestrous cycle (Kahle
and Parvizi, 1993).

Results of the study of µ  and δ opioid receptor densities in brainstems of piglets
between 2 and 21days old show that the binding characteristics of each receptor
remained unchanged over the age-range. Delta opioid receptor density was minimal in
young (2-7 days old), and increased over the age-range studied. Mu opioid receptor
density exceeded the delta opioid density in young (2-7days old) and old (20-21days
old) piglets. It was concluded that the development of delta opioid receptors in swine
lags behind that of the mu opioid receptors (Laferriere et al., 1999). The putative
epsilon (ε) receptor has also been identified in forebrain of the pig. It is proposed that
the epsilon (ε) receptor is more abundant than the µ, δ, κ opioid receptor types in the
forebrain of pig (Nock et al., 1993).
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Although endogenous ligands for the σ-opioid receptor have not yet been isolated,
results of binding studies with exogenous ligands of σ receptors revealed their
existence in the gastric fundic mucosa in pigs  (Harada et al., 1994). Recently, Osinski
et al., (1999) showed that the opioid receptor-like-1 (ORL-1) for the endogenous
ligand nociceptin is expressed in the porcine cerebral cortex, kidney and the ileum.
Other opioid receptors like the gamma and Zeta opioid receptors are rather rare or
absent in the pig.

1.3    The mechanism of Opioid Ligand-Receptor interaction in
         modification of cell function.

Opioid receptors are allosteric proteins (ligand binding sites) interacting with
extracellular physiological signals (opioid ligands) and converting them into
intracellular effects leading to modification of cell function (Barnard and Simon,
1993). Hucho (1993) proposed the triune receptor model in which three functional
moieties interacted to modify cell activity. The three functional moieties included :
a signal receiving "R" (receptor or binding site) part, an effector "E" (ion channel or
enzyme), and a transducer "T" (G-protein) coupling "R" and "E" and transducing the
signal from binding site to the effectors. The transmitter (opioid ligand) is recognised
and bound at the extracellular surface of the receptor at the cell membrane. The
transducers are mostly G-proteins which in turn transduce stimulatory (Gs) or
inhibitory (Gi or Go-) effects to the effectors. The G-proteins are known to couple
specific receptors and possess α, β and γ subunits (Childers, 1991). The effector
system is either an ion channel (Na+, Ca2+, K+) and/ or an enzyme (phospholipase C or
adenylate cyclase). The activation of opioid receptors by agonist ligands generally
inhibits neuronal excitability through inhibiting Ca2+ channels and activating k+
channels (Satoh and Minami, 1995). The affinity of opioid receptors for opioid
agonists is decreased by sodium ions, whereas that for antagonists is rather enhanced
(Pert and Synder, 1974). The binding of opioid agonists to G-proteins coupled
receptors cause stimulation (Federmann et al., 1992, Kaneko et al., 1994) and
inhibition (Childers, 1993) of adenylate cyclase.
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1.4.0  Endogenous opioids and luteinizing hormone secretion

It has been established that endogenous opioids play a significant role in modulating
gonadotropin secretion (for review see, Brooks et al., 1986a). The first evidence
suggesting that opioids inhibit LH secretion was derived from experiments in which
the effects of opioid receptor agonists and antagonists on LH secretion were
evaluated. Bruni et al., (1977) showed that naloxone, an opioid receptor antagonist,
increased release of LH and FSH in male rats and this effect was prevented by
concomitant administration of met-enkephalin.

Effects of opioids on LH are sex-, age-, and species-dependent. Furthermore other
intrinsic and extrinsic factors like steriod hormone concentration, nutrition,
photoperiod and stressors may interplay to modify opioid effects on LH secretion
(Britt et al., 1993).
Intravenous administration of naloxone increased, whereas morphine reduced LH
pulse frequency in sheep (Ebling et al., 1989). Similarly, intracerebral  administration
of naloxone enhanced LH secretion (Malven et al., 1990), whereas ß-endorphin
injected into the cerebroventricular system decreased LH secretion in sheep (Horton
et al., 1990). Opioid modulation of LH is predominantly probable via the
hypothalamic-pituitary-axis. Data supporting this presumption showed that naloxone
increased LHRH in hypothalamo-hypophysial portal blood in sheep (Horton et al.,
1989). In addition morphine failed to decrease LH secretion in sheep bearing
hypothalamo-pituitary disconnections (Horton et al., 1990).

In the prepubertal ewe lamb,  naloxone had no influence on LH secretion.
Interestingly, as ewes approached puberty, naloxone could increase LH pulse
frequency and mean serum LH concentrations (Rawlings et al., 1993). Whereas in the
prepubertal male lamb, naloxone treatment resulted in an increase in LH pulse
amplitude at age from 5-10 weeks. Surprisingly, at 10 weeks of age, naloxone caused
a decrease in LH secretion. Nevertheless, at 25 weeks of age naloxone increased LH
pulse frequency (Rawlings et al., 1991).
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Similarly, prepubertal bulls and heifers responded to naloxone treatment with
increases in LH pulse frequency (heifers) and LH pulse amplitude and basal serum LH
concentrations (bulls) (Evans et al., 1991; Rawlings et al., 1993). However, Gazal and
Anderson, (1995) reported that injection of naloxone had no effects on plasma LH
secretion in prepubertal heifers. The difference in results obtained in both studies is
related to age at which treatment was given. While, Rawlings et al. (1993) gave
naloxone between 4-18 weeks, Gasal and Anderson (1995) administered naloxone at
32 weeks of age. At 32 weeks of age, sudden rises in progesterone concentration
prior to first oestrus may act negatively to reduce LH secretion from the pituitary
(Rawlings et al., 1993).

Cicero et al., (1993) reported that naloxone did not reverse the supressive-effects of
morphine on serum LH levels in the prepubescent rat whereas it fully reversed this
effect in the adults. They propounded that the effects of opiates on the hypothalamic-
pituitary-axis in pre- and postpubertal male rats could be age-dependent. They
suggested that the effects of morphine and naloxone on LH secretion could be
mediated by different receptors at the pubertal stage, but in adults they act at the  same
receptors. It was concluded that morphine suppresses LH secretion at very early stages
of development well before puberty, whereas naloxone does not increase LH secretion
until after puberty (Cicero et al., 1993).

A specific delta-opioid receptor agonist, [D-Pen2, D-Pen5]  enkephaline: DPDPE, was
found to abolish the LH surge in the hypothalamus of the female rat. Naloxone
reversed the inhibitory effect of DPDPE. It was concluded that the activation of δ-
opioid receptors may exert an inhibitory effect on LH release probably via
monoaminergic systems as they are parallely suppressed by DPDPE in all the
hypothalamic regions investigated (Yilmaz et al., 1998).
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Application of opioids at different periods of the oestrus cycle in female animals has
shown different responses of LH secretion indicating a role of steriod hormone
concentration. During the follicular phase of the oestrus cycle, the opioid agonist,
morphine and the met-enkephalin analogue, FK 33-824 inhibited LH secretion in
heifers (Brooks et al., 1986a; Armstrong and Johnson, 1989). Similarly,
intracerebroventricular administration of ß-endorphin to ovariectomized or intact 
ewes in the follicular phase of the oestrus cycle also caused inhibition of LH secretion
(Horton et al., 1989). Likewise in the male castrated sheep, the opioid agonist, FK 33-
824 decreased both average and episodic LH secretion in both acute and chronic
treatments (Armstrong and Spears, 1991). These results suggest that opioid agonists
exert inhibitory effects on LH secretion independent of the steriod hormone
concentration during the follicular phase of the oestrus cycle in the cow and sheep.

On the otherhand, the opioid antagonist, naloxone increased LH concentrations in
ewes with luteal phase concentrations of progesterone, but not in ewes with low
concentrations of progesterone. These results led to the assumption that the negative
feedback actions of progesterone on tonic LH secretion may be mediated by
endogenous opioids (Malven et al., 1984). In another study, intravenous infusion of
naloxone resulted in an increase in LH pulse frequency in ovariectomized ewes that
were not pretreated with steriods and in those pretreated with progesterone and
oestradiol. However, when oestradiol was given alone, no effect of naloxone was seen
(Currie et al., 1991).

In the cyclic intact ewe, naloxone treatment increased basal LH secretion and LH
pulse amplitude during the luteal phase of the oestrus cycle. During the follicular
phase, naloxone increased LH pulse amplitude but decreased LH pulse frequency
(Rawlings et al., 1993). It seems that opioid antagonists elevated LH concentrations in
both the luteal and follicular phases of the oestrus cycle in intact cyclic ewe. However,
LH parameters (LH pulse frequency and LH pulse amplitude) are continously
fluctuating at different periods of the oestrus cycle.
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Results of Rawlings et al., (1993) also revealed that in the ram, naloxone increases LH
secretion in an age-dependent manner. A higher level of testosterone in adult males
inhibits LH secretion, whereas in the young ram lamb, opioidergic effects are steriod-
independent.

The LH response to opioid agonists or antagonists in postpartum suckled cows
probably depends on the stage of postpartum and whether calves are suckling during
the treatment period. Peck et al., (1988) reported that an injection of morphine
(1mg/kg) or a 7-hour infusion of morphine (15mg.kg.-1h –1) suppressed LH in cows
whose calves had been weaned 36 hours before treatment. This is because the
endogenous opioid  tone caused by suckling is lowered after weaning. Thus, one
would expect opioid agonists to cause suppression in LH secretion in suckled cows
only if the suckling was not fully suppressive already. On the otherhand, when
naloxone was given 48 hours after transient weaning on day 35 postpartum, the LH
response differed between cows nursing calves and those from which calves had been
weaned (Whisnant et al., 1986). In cows being nursed, basal LH was already
suppressed due to the suckling-induced effect and naloxone induced a threefold
increase in LH secretion. In cows whose calves were weaned 48 hours before
treatment, naloxone had no effect because weaning already increased basal LH
threefold and no further increase could be achieved. In contrast, however, Rund et al.,
(1989) reported that naloxone increased LH concentrations in both suckled and
nonsuckled cows. It can be concluded that opioid agonistic inhibitory effects and
opioid antagonistic stimulatory effects on LH secretion in the postpartum cow is
suckling-dependent. The opioidergic inhibition of LH release in suckled cows depends
on the time post partum that drug is given. This inhibition seems to decrease slowly
with time post partum, whereas opioid antagonistic stimulatory effects on LH
secretion probably increases with time post partum.
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1.4.1  The effects of endogenous opioids on LH  secretion from fetal
to prepubertal stages in the pig.

In the fetal pig, LH gene expression starts at around day 45-50 p.c. (Ma, 1991). 
Endogenous opioid genes switch on as early as day 35 p.c.(Pittius et al.,1987) and
opioid receptors can be detected as from around day 50 p.c. (Kahle and Parvizi, 1993).
The hypothalamus takes over control of LH around day 80. Electrical or
electrochemical stimulation of the hypothalamus causes a LH surge around day 80.
Stimulation of the hypothalamus around day 60 was ineffective (Bruhn et al., 1983).
As development of the fetus continues, the pituitary becomes more responsive to
hypothalamic releasing factors (Colenbrander et al., 1982). In the fetal pig, regulation
of LH is more or less not affected by fetal steriods. Hence, fetal gonadectomy
(Ponzillius et al. 1986) or estradiol-17ß treatment (Parvizi et al., 1986) do not alter the
LH secretory pattern. Opioidergic control of LH begins as soon as the opioid receptors
become functional.
The predominant opioid receptors are of the kappa and mu-subtypes. Unlike in the
fetal sheep (Yang and Challis, 1991) where the delta-opioid receptor is more
important, the fetal pig has virtually no δ-opioid receptor (Kahle and Parvizi, 1993). 
It has been observed that towards the end of pregnancy, morphine acutely inhibits the
secretion of LH in male and female fetuses. Daily treatment of fetuses with morphine
over a period of 14 days before birth caused an inhibition of basal LH in females,
while male fetuses were unaffected (Behrens-Herrler and Parvizi, 1992). Co-
administration of naloxone and morphine reversed the long term morphine-induced
inhibitory effect on LH secretion in females. Administration of a single injection of
naloxone had no effects on LH secretion in both female and male fetuses. However
repeated injections of naloxone over a 7 day period surprisingly decreased LH
secretion in males whereas females remained unaffected.  The paradoxical long-term
inhibitory effect of naloxone on LH secretion in male fetuses indicates the age-
dependent function of opioid receptors. The authors suggested that the link between
opioids and the luteinizing hormone system is functional in the pig from at least 2
weeks before birth (Behrens-Herrler and Parvizi, 1992).
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Trudeau et al., (1988) observed no influence of morphine and /or naloxone on the
secretion of LH in intact and castrated immature 6 weeks old male pigs. Naloxone
also failed to alter LH secretion in intact prepubertal gilts and in ovariectomized,
progesterone-treated prepubertal gilts (Barb et al.,1988). However, LH secretion
increased when gilts were ovariectomized prepubertally and treated with progesterone
and naloxone at a chronological age when puberty occurred in intact gilts (Barb et al.,
1988).

In contrast to the above-mentioned work of Barb et al.,(1988), intracerebroventricular
administration of morphine (Estienne et al., 1990) in ovariectomized gilts resulted in a
decrease in serum LH concentration and serum LH pulse frequency. However, the
serum LH pulse amplitude did not change.

Prunier et al., (1990) reported that administration of naloxone to male and female
piglets (8-10 days) caused a reduction in the concentration of circulating LH levels 
in both sexes. Leu-enkephalin showed no effect. Further investigation with 42- 47days
old male piglets showed inhibitory effects of naloxone on LH secretion in intact and
castrated testosterone-substituted animals. In contrast, Leu-enkephalin was only
effective when the animals were castrated and received no steriod (Kahle et al., 1989).

1.4.2   Endogenous opioids and luteinizing hormone secretion in the
           adult pig

In the adult pig, opioid agonists generally inhibit LH secretion whereas opioid
antagonists enhance LH release. However, slight variations in LH response to opioids
are observed in the adult female depending on the reproductive stages. On the
otherhand, LH response to opioids in adult males has a more consistent pattern but
may differ in castrated or intact males. In the adult female pig, intracerebroventricular
administration of the opiate agonist morphine reduced LH secretion in both
ovariectomized mature and prepubertal gilts. Treatment with naloxone stimulated
luteinizing hormone  release in mature but not in prepubertal gilts (Barb et al., 1989).
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As mentioned above, the modulation of LH secretion by endogenous opioids is
strongly related to gender, age and level of steriod hormones in the pig. The steriod
hormone concentration in female animals influences  the opioidergic modulation of
the release of luteinizing hormone. The application of microinjections of met-
enkephalin into the mediobasal hypothalamus showed no effect on LH secretion in
pig. However pre-application of oestradiol-17ß and testosterone resulted in a
significant decrease in LH concentration (Parvizi, 1989).

The microinjection of ß-endorphin (30ng) into the hypothalamus or amygdala  of
ovariectomized miniature pigs revealed that it is not the hypothalamus but the
amygdala in which ß-endorphin becomes effective. However simultaneous micro-
injection into the hypothalamus and amygdala showed that inhibition of pituitary LH
secretion was exacerbated as compared with the inhibitory effect observed when
microinjections were carried out into the amygdala alone (Parvizi and Ellendorff,
1980). Naloxone enhances plasma LH levels when injected into the mediobasal
hypothalamus of cyclic sows (during dioestrus) but not in ovariectomized sows
(Parvizi, 1988). ß-endorphin may modulate LH release independently from gonadal
steriods in male and female pigs, whereas leu-enkephalin and met-enkephalin actions
are most probably steriod-dependent (Parvizi, 1989). These results demonstrate that
opioid actions are not only sex-, steriod hormone concentration-dependent but also
vary with route or site of administration of drug.

The administration of naloxone and met-enkephalin analogue (FK 33-824) injections
did not affect LH secretion during the early or late follicular phase in gilts. However,
continous infusion of FK 33-824 for 4 hours decreased LH secretion during the late
follicular phase of the oestrus cycle (Okrasa et al.,1992). On the otherhand, a single
injection of FK 33-824 decreased the number of LH pulses over a 3 hour period in the
luteal phase. Morphine exerted an inhibitory effect on the estradiol benzoate (EB) -
induced LH surge during the positive feedback phase, 60-64hours after EB
administration, in ovariectomized gilts. Administration of naloxone in ovariectomized
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gilts during the negative feedback phase (30-34 hours after EB administration) did not
alter LH secretion. These results indicate that endogenous opioid petides participate in
the regulation of LH in the oestrus cycle in the gilt (Okrasa et al. 1992). On the
otherhand, naloxone was found to stimulate LH secretion in the luteal phase but not in
the early and late follicular phases in gilts (Barb et al., 1986a ; Okrasa et al., 1990).

During pregnancy, luteinizing hormone secretion is relatively high but towards the
last month of pregnancy the LH secretion is depressed (Quesnel and Prunier, 1995).
At the end of gestation, Willis et al., (1996) reported that naloxone increased LH
concentration in sows. After partuirition, LH secretion increases but is again inhibited
by the establishment of lactation (Quesnel and Prunier, 1995).

Mattioli et al., (1986) injected naloxone through indwelling vena cava canulla in
lactating sows on day 15 postpartum. Naloxone induced an increase in LH secretion
within 20-50 minutes. The authors concluded that endogenous opioids are involved in
modulating the endocrine patterns occuring during lactation, that is, down regulation
of LH secretion. Similarly, infusion with naloxone or transient weaning elicited a
threefold increase in the frequency of LH pulses although neither pulse amplitude nor
average concentration of LH was significantly altered  in lactating sows (Britt et
al.,1993). The authors assumed that the infusion of naloxone accelerated the GnRH
pulse generator but the amount of GnRH released during each pulse was not altered.
After weaning, naloxone was found to increase mean LH concentrations when
administered into sows (De Rensis and Foxcroft., 1999a).
              
On the otherhand, Britt et al., (1993) reported that infusion of morphine into sows
nursing piglets tended to reduce LH pulse frequency. When morphine administration
was combined with transient weaning, LH pulsatility was depressed further.
Similarly, morphine administration resulted in a decrease in LH secretion in suckling
sows and in zero-weaned (piglets removed immediately after farrowing) sows (De
Rensis et al., 1999b). The authors concluded that the suckling stimulus is associated
with suppression of LH secretion immediately after birth. However, chronic naloxone
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treatment on lactating sows was found  to reverse the suckling-induced inhibition of
LH secretion in the early post partum period. The naloxone-induced increase in LH
secretion was observed on day 10-11 of lactation (De Rensis et al., 1993, 1998). It can
be suggested that opioid antagonist effects on LH secretion are dependent on the
steriod environment, stress (suckling) but LH response to opioid agonist effects are
apparently steriod hormone or suckling-independent.

1.4.3  In vitro effects of opioids on luteinizing hormone secretion

There is very little information on opioidergic effects at the pituitary level in vitro in
the pig. For this reason, the literature has been reviewed on other animal species.

A number of controversial reports and observations of paradoxical effects of opioids
suggest that a direct action at the pituitary level cannot be ruled out (Blank et al. 1986,
Cacidedo and Sanchez-Franco, 1986, Chao et al. 1986, Barb et al. 1990, Dragatsis et
al. 1995). Interestingly, the administration of ovine ß-endorphin and human ß-
endorphin to the ovine pituitary cells caused stimulation of LH (Matteri and Moberg,
1985). The LH secretion induced by hß-endorphin was found to be dose-dependent.
However, naloxone pretreatment did not reduce the hß-endorphin-induced LH
secretion (Matteri and Moberg, 1985).

The direct effect of human ß-endorphin on LH secretion at the pituitary in the rat
seems to be different from that of the sheep. Cacicedo and Franco Sanchez (1985)
showed that treatment with human ß-endorphin inhibited LH secretion from rat
pituitary cells after 24 hours. The inhibition was dose-dependent and more evident
after 48 hours.         
        
Interestingly, naloxone enhanced LH secretion and also blocked the human ß-
endorphin-induced inhibitory effects. The administration of met-enkephalin and D-
ala2-met-enkephalinamide (DALA) also produced a significant decrease in LH
secretion. (Cacicedo and Franco Sanchez, 1985).
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Morphine sulfate was found to have a direct inhibitory effect on both basal and
GnRH-stimulated LH release by cultured female rat pituitary cells. The inhibitory
effect was prevented by the opiate antagonist, naltrexone.  Treatment of cells with
naltrexone or ß-endorphin antiserum significantly increased basal LH release (Blank
et al., 1986).

The administration of naloxone in bovine pituitary cell culture increased basal
secretion of LH after 2 hours but not after 24 hours of culture.  Addition of met-
enkephalin into the culture suppressed basal LH release (Chao et al.,1986).

Naloxone increased LH release from porcine pituitaries after 4hours and 24hours of
cell culture. When GnRH was simultaneously given with naloxone, the increase was
greater than after GnRH alone after 4hours but not after 24hours. Beta-endorphin
failed to alter basal LH secretion after 4hours but decreased secretion after 24hours
(Barb et al., 1990).

The µ-opioid agonist DAGO, inhibited the release of LH from rat pituitary in a
concentration-dependent manner. When naloxone and DAGO were concomitantly
administered, the inhibitory effect of DAGO on LH release was abolished. The
release of LH induced by D-Ala6-LHRH was also inhibited by DAGO, although this
was not effective at low concentrations. These results demonstrate a mu-opioid
receptor-mediated effect on  the spontaneous and GnRH-induced release of LH at the
pituitary level in vitro (Dragatsis et al., 1995). On the otherhand, the delta-opioid
peptide agonist DSLET did not modify the spontaneous release of LH. Surprisingly,
GnRH analog, D-Ala6LHRH-induced LH release was inhibited by subsequent
administration of DSLET. The delta-opioid antagonist, diallyl-G blocked this
inhibition (Dragatsis et al., 1995).        
                
In contrast to the results obtained using mu and delta agonists, the kappa opioid
agonist, U-50488H increased the spontaneous LH release in a concentration-
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dependent fashion. Simultaneous addition of the specific kappa-opioid antagonist,
MR-2266 and U-50488H attenuated the stimulatory effect. Interestingly, the kappa
opioid agonist U-50488H did not show any effect on the GnRH analog-induced LH
release (Dragatsis et al., 1995).

According to several results obtained so far, opioidergic control of  LH is not solely
via the hypothalamo-pituitary axis.  Direct effects of opioids can be seen at the
anterior pituitary level. These opioid effects depend on type of opioid peptide, opioid
receptors and the animal species.

1.5.0  Endogenous opioids and growth hormone secretion

Growth hormone is mainly regulated by two hypothalamic peptides, namely: Growth
hormone releasing hormone (GHRH or GRF) which stimulates GH  secretion (River
et al., 1982 ; Guillemin et al., 1982) and Somatotrophic releasing inhibiting hormone
(SRIH) also known as somatostatin, that inhibits GH release (Brazeau et al., 1973).
Supportive data indicate that hypophysectomy or active immunization against growth
hormone releasing factor retards normal growth in cattle and pigs (Simpson et al.,
1991).

However, other peptides including insulin growth factors (IGFs), neuroactive amino
acids and endogenous opioid peptides are also involved in the direct or indirect
modification of growth hormone release from the pituitary gland (Simpkins et al.,
1993).

Several reports have documented the involvement of endogenous opioid peptides in
the regulation of growth hormone in farm animals and humans. In addition, most
studies indicate that opioids stimulate growth hormone via a stimulatory tone on GRF
(Wehrenberg et al., 1985, Armstrong et al., 1990) and an inhibitory tone on
somatostatin (Drouva et al., 1981, Villa et al., 1997). Nevertheless, a direct
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opioidergic effect on the anterior pituitary secretion of growth hormone cannot be
excluded (Armstrong et al., 1990; Villa et al.,1997).

Opioids generally elevate circulating GH in farm animals (Armstrong et al., 1993) and
in human (Grossman, 1983, Schulte et al., 1993). Opioid activation of GH probably
involves the delta binding sites (Koenig et al., 1984) and µ  but not k-receptors
(Krulich et al., 1986). It is well known that endogenous opioids play an important role
in the growth of developing, neoplastic, renewing and healing tissues, both in
prokaryotes and eukaryotes (Zagon and Mclaughlin, 1989) in addition to serving as
neuroregulators (Zagon et al.,1996).

A synthethic analog of leucine enkephaline-hexapeptide, dalargin was shown to
stimulate healing of skin wounds in rats, dogs and mini-pigs at local and parenteral
administration. The proliferation rate of mitotic division of fibroblast was greatly
increased. Early and active growth of vascular elements, rapid maturation of
granulation tissue and accelerated epithelization were also observed. The authors
suggested that the opiate agonist could increase GH secretion and thus growth activity
in animals (Il’inskii, et al., 1987).

The opioidergic modulation of GH secretion also depends on the age-, sex-, steriod
hormone level, stress (food restriction etc.) and photoperiod in seasonal variation
(Rushen et al., 1993, Aurich et al., 1999). It is interesting to note that opioid-induced
effects on GH secretion apparently vary slightly with the different routes of
administration of treatment and  animal species investigated (Zhai et al.,1995).

1.5.1  The effects of endogenous opioids on growth hormone 
        secretion from fetal to pubertal stages.

Owing to lack of a broad scope of literature on the effects of endogenous opioids on
GH secretion in the pig, the literature for other animal species is also reviewed
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hereafter.  In the neonatal female and male rat, the mu-agonist, morphine and kappa
agonist U50-488H caused a stimulation and an inhibition of GH secretion on postnatal
day 10 respectively. It was observed that kappa-inhibition was already effective as
early as postnatal day 2, but mu-stimulation was not substantial until postnatal day 10.
The intracerebroventricular (i.c.v.) administration of the mu-selective peptide [D-
Ala2-Nmet-Phe4-Gly-ol]- enkephalin (DAMGO) elicited a marked rise in GH
secretion, while administration of the delta-agonists [D-pen2D-pen5]-enkephalin
(DPDPE) or deltorphin II caused only a minor and non-dose-dependent increase in
GH secretion in the neonatal rats (Eason et al., 1996). When older pups were
administered DAMGO intracerebro-ventricularly on postnatal day 20, GH secretion
was stimulated. On the otherhand, neither DPDPE  nor deltorphin II consistently
increased GH secretion on postnatal day 20 in female and male rats. Furthermore,
peripheral administration of either morphine or the highly selective mu-agonist,
sufentanil elicited marked GH secretion on postnatal day 20, but only combined
administration of the µ-opioid receptor antagonist beta-funaltrexamine (beta-FNA)
and the delta-opioid receptor antagonist natrindole substantially diminished GH
responses to morphine and sufentanil. These results suggest that both mu-and kappa-
opioid receptors are involved in the regulation of GH secretion in neonatal rats. While
delta-receptors do not play a significant independent role in this response, they may
act synergistically with mu-receptors in producing stimulation (Eason et al., 1996).
             
In prepubertal heifers at 8-9 months of age, the opioid agonist FK 33-824 caused a
4-5 fold increase in GH secretion (Simpson et al., 1991). Interestingly, the response
of GH to the opioid agonist, FK 33-824 was greater at 8 months than at 9 months of
age (Armstrong et al., 1993). The authors suggested a possible desensitization of
growth hormone to opioid effects with increasing age.
           
Serum concentration of GH was elevated in 4-10 months old heifers after i.c.v.
morphine injections. An equimolar dose of naloxone reverted the morphine-induced
increase in GH secretion. Application of naloxone showed no dose-related effects. All
doses of naloxone decreased serum GH concentration in older (234 ±6days) heifers
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but proved ineffective in younger (86 ±11days) heifers. These results suggest an age-
related naloxone effect on GH secretion in heifers (Leshin et al., 1990).

In contrast to results observed in rats (Eason et al., 1996) in heifers (Simpson et al.,
1991) and in pigs (Barb et al.,1992, Parvizi et al.,1995) plasma concentrations of
growth hormone were found to decrease following intravenous administration of
morphine sulfate in young chickens. The opiate antagonist naloxone had no
stimulatory effect on basal GH concentrations but attenuated the GH response to
morphine (Harvey & Scanes, 1987). These results indicate that opioid effects in
control of GH release in young chickens are probably inhibitory.

In the fetal pig, growth hormone gene expression can be seen in the pituitary as early
as day 45 p.c (Ma, 1991). Opioidergic control of pituitary GH release could be
estimated to become effective as from day 55 onwards in the fetal life (Ma, 1994).
During fetal development, the fetuses display higher plasma GH and IGF-I levels than
their sows. It was observed that the levels of GH fall within a few days after birth
(Bauer and Parvizi, 1996). Dispite these high levels of GH in fetuses, GRF (10µg/kg,
GRF 1-29NH2) induced a dramatic GH surge as from day 80 p.c. and later in
gestation, as well as in neonates. The GRF-induced GH peak reached 134 ± 12µg/ml
in fetuses and 43 ± 4µg/ml in neonates. On the otherhand, somatostatin (1-14 cyclic)
given as a bolus injection (50µg/kg) followed by  5 subsequent injections (25µg/kg
each) at 5 minutes interval neither inhibited basal nor GRF-induced GH release in
fetal as well as neonatal pigs.       

The somatostatin inhibitory pathway is still premature in the fetal pig (Parvizi et al.,
1995). Inhibition of GH secretion could only be achieved by passive immunization
with GRF antibody. Surprisingly an enhancement of plasma GH concentration
occured during and after somatostatin application in some piglets (Parvizi et al.,
1995).
When naltrexone and morphine were administered to chronically catheterized fetal
(1mg/kg/daily) and neonatal (1mg/kg/single shot) pigs, naltrexone showed no effects
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whereas morphine exhibited remarkable changes on GH secretion. In fetuses daily
injections of morphine over 3-4 days were essential to prime the brain/ pituitary to
initiate a GH response. A single injection of morphine was ineffective before day 16
p.p. but stimulated GH secretion in piglets older than 16 days. The authors concluded
that GH stimulatory systems seem to be functioning prior to birth, whereas the
somatostatin inhibitory axis is apparently far from maturation at parturition (Parvizi et
al., 1995).

In the immature 6 weeks old male pig, morphine treatment  resulted to an increase in
GH levels. Although naloxone alone did not affect GH levels, it’s administration
immediately after morphine delayed the GH increment seen in morphine treated pigs
(Trudeau et al., 1988). Similarly, in prepubertal gilts, intracerebroventricular injection
of morphine and intravenous administration of FK 33-824 stimulated a rapid increase
in serum growth hormone secretion (Barb et al., 1992; Armstrong et al., 1993). 

On the otherhand, intravenous injections of naloxone to prepubertal gilts under stress
condition inhibited stress-induced GH increase. It was concluded that endogenous
opioids enhance GH response to stress in pigs (Rushen et al., 1993). It could be
concluded that opioids participate in the control of GH release in the immature animal
and GH response becomes more effective with increasing age. 
           
1.5.2      The effects of endogenous opioids on growth hormone
secretion in adults.

The opioid modulatory effects on GH parameters has been studied in the females at
different periods of the oestrous cycle, gestation, lactation and postpartum.
Interestingly, results in most species  studied so far showed sex-and species-
differential effects at different physiological states of the female animal. Whereas
male animals  showed a more consistent pattern of GH release in response to opioid
treatments.
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Plasma concentrations of growth hormone (GH) were found to increase following
intravenous administration of the mu-agonist morphine in male and ovariectomized
female rats (Terry et al., 1982; Koenig et al., 1983 and Krulich et al., 1986). The
opiate antagonist, naloxone had no stimulatory effect on basal GH concentrations but
attenuated the stimulatory effect of morphine on GH secretion. On the otherhand,
bremazocine and U-50-488, two selective kappa receptor agonists suppressed GH
release at high doses (Krulich et al., 1986).

Simpkins et al., (1993) reported  that chronic morphine exposure of male rats caused a
12-fold increase in basal GH levels and a modest rise in GH pulse frequency. The
mean concentration of GH secretion increased 3-fold over the 6 hours experimental
period. On the contrary, in female rats, administration of chronic morphine reduced
GH pulse amplitudes but did not significantly affect other parameters of GH secretion.
A sex-differentiated effect of morphine on GH secretion can be seen in the adult rat.

Zhai et al., (1995) continuously infused male sprague-dawley rats with morphine
through subcutaneous implanted mini-osmotic pumps over a period of 5 days. They
found that acute administration of morphine significantly decreased the density of
growth hormone binding sites in choriod plexus and hypothalamus. The plasma levels
of GH correlated negatively with the density of binding sites in these regions of the rat
brain. The same authors administered intermittent injections of morphine intracerebro-
ventricularly (icv) and subcutaneously (s.c) and observed a similar decrease in rGH
binding. They noticed a differential time course of response between the two routes of
administration, with intracerebroventricular (i.c.v.) injections achieving faster
response than subcutaneous (s.c) treatment.

In an attempt to determine if the growth hormone response to morphine sulphate could
be affected during steriod-induced LH surges, Singh et al., (1992) provided evidence
that gonadal steriod treatment which induce  a surge in LH secretion in female rats
suppressed opiate-induced increase of GH secretion. This dampening of opiate-
induced GH secretion is confined to the time of the steriod-induced LH surge. The
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authors concluded that ovarian steriod-induced increase in LH do not only blunt
morphine modulation of LH secretion but also affects opioid-induced GH release in
rats (Singh et al., 1992).

The endogenous opioid, met-enkephalin, has been found to interact with zeta (ζ)
opioid receptors to influence growth both in vivo and in vitro in rats. Unlike most
opioids, met-enkephalin also termed “Opioid Growth Factor” (OGF) serves as a
negative modulatory agent in cell proliferation, migration, differentiation and survival.
It is presumed here that met-enkephalin maintains a continuous tonic effect on growth
events since suppression of met-enkephalinergic tone with naltrexone results in a
stimulatory response in growth. Furthermore, developing and adult rats exposed
prenatally to naltrexone were not analgesic after morphine challenge and exhibited a
marked decrease in µ-opioid receptors (Zagon et al., 1998).

In a study, steers (castrated bulls) were administered two i.v injections of FK 33-824
(2.3µg/kg) 1 hour apart. The first but not the second, injection of FK 33-824 caused a
four- to six-fold increase in GH concentration (Armstrong and Spears, 1991). In a
subsequent study by the same authors, wethers (castrated rams) were administered FK
33-824 via two s.c. or i.v. injections (1 hour apart), or wethers were infused (i.v.) with
FK 33-824 (8µg/kg/h) for 2 hours. In contrast to the results in steers, both injections
of FK 33-824, either i.v. or s.c. elicited an increment in GH release in wethers.
Furthermore,  acute i.v. infusion of FK 33-824 (8µg/kg/h) stimulated GH during the 2
hours experimental period in wethers. When wethers were chronically administered
(s.c.) a low (3µg/kg/h) or high (12µg/kg/h) dose of FK 33-824 for 7 days, the high
dose but not the low one stimulated GH secretion during the first 4 hours. However,
by 48 hours after initiation of treatments, concentrations of GH were similar in
control, low and high-dose wethers. The authors speculated that neurones mediating
the effects of endogenous opioid peptides on GRF became tolerant to continous
exposure to FK 33-824 (Armstrong and Spears, 1991).
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During the follicular phase in heifers, morphine and the met-enkephalin analogue
FK 33-824 stimulated GH secretion within 60 minutes after injection (Armstrong et
al., 1993).
At the beginning of gestation, plasma GH concentrations remain high and these high
levels are maintained throughout pregnancy. Surprisingly, naloxone induced a
significant increase in GH around day 280 but not at an earlier or a later period in
ovary-intact and pregnant mares (Aurich et al., 1999). In contrast, naloxone decreases
GH secretion during pregnancy in rats (Miki et al., 1981) as well as in cattles and pigs
(Armstrong et al., 1993). These results indicate that GH release at gestation is partly
influenced by an opioid tone that may be stimulatory or inhibitory at particular periods
during pregnancy depending on the animal species.

During lactation, serum concentrations of growth hormone is elevated in ruminants
and swine. Nevertheless, activation of opioid receptors with FK 33-824 stimulated
growth hormone secretion in cows (Armstrong et al.,1991).
In the postpartum cow, administration of FK33-824 significantly elevated GH
secretion on day 47 and 121, but not on day 19 postpartum. This result indicates that a
shift in endogenous opioid tone on GH secretion is apparent in the postpartum cow
(Armstrong et al., 1991). Surprisingly, when naloxone was administered on days 19,
47 and 121 postpartum, a decrease in GH secretion was only observed on day 47 p.p.
(Armstrong et al., 1991). In another study, 3 injections of naloxone were administered
to lactating beef cows on day 27, 51, 91 and 110 postpartum. Serum growth hormone
levels were unaffected by naloxone (Moore et al., 1992). Although, opioid agonists
clearly stimulated release of GH, the response to naloxone showed  that elevated
growth hormone during lactation in the cow is not likely solely the result of elevated
endogenous opioids. Nevertheless, the possibility exists that receptor subtypes not
affected by naloxone are involved in the regulation of growth hormone  in the cow
post partum.
The role of opioid peptides on GH response to stress in nursing sows was investigated.
Results disclosed that piglet removal and restraint (nose-snare prohibition) decreased
GH secretion in sows. Treatment of sows with naloxone injections (i.v. 2mg/Kg) was
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 found to decrease GH concentration. But return of piglets to sows augmented the GH
release again. The rise in GH release following piglets’ return was abolished by the
combination of restraint and naloxone. This indicates that endogenous opioids may
comprise one of the stimulatory pathway leading to GH increment during stress in
sows (Rushen et al., 1995).

1.5.3 Interaction of opioids and GHRH in the control of growth
hormone secretion

Majority of the studies performed to investigate the role of opioids on GHRH or
GRF-induced GH secretion have been carried out on humans and rats. Information on
the interaction of opioids and the hypothalamic releasing hormones in the pig is
scarse.

Several studies indicate that endogenous opioids participate in the regulation of
growth hormone release through down- and up-regulatory mechanisms of the two
hypothalamic neuropeptides: growth hormone releasing hormone (Barbarino et al.,
1987, Delitala et al., 1989, Armstrong et al.,1990, Vaccarino and Taube, 1997, Tomasi
et al., 1998) and somatostatin (Wehrenberg et al., 1985, Armstrong et al., 1990).

When adult rats were passively immunized against GRF, a complete inhibition of GH
stimulatory response to morphine and ß-endorphin occured. From these results, the
authors suggested that opioid peptide stimulation of pituitary GH secretion is
mediated through hypothalamic GRF (Wehrenberg et al., 1985). Furthermore,
administration of morphine appeared to increase the GRF-induced GH release in male
rats (Vaccarino and Taube, 1997).

In human, the endogenous opioid, ß-endorphin was found to enhance GHRH-induced
GH secretion in prepubertal children but not in pubertal children (Pugliese et al.,
1992). Similarly, ß-endorphin infusion into adult human males enhanced GH response
to GHRH (Schulte et al., 1993). The effect of the met-enkephalin analogue (G-
DAMME) on GH response to GHRH  in normal men was studied. Simultaneous
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 administration of the opioid agonist G-DAMME and GHRH caused a higher GH
response than when G-DAMME or GHRH was given alone. Since the GHRH-(1-
29)NH2 dose (100µg) used was a maximally stimulatory one, the authors suggested
that the enhancing effect of G-DAMME on GHRH-induced GH release may be
mediated through inhibition of somatostatin release (Delitala et al., 1989).

The effect of chronic naltrexone treatment on GH secretion in normal human females
(25-38yrs old) revealed that long term opioid receptor blockade has an inhibitory role
on GHRH-induced GH secretion but showed no effect on basal GH release. The
inhibition of GHRH-induced GH release without interference with GH basal level
could indicate that opioids regulate only GH dynamics. The authors presumed that an
opioid-induced enhancement of somatostatin activity or secretion could be responsible
for the differential effect of naltrexone on GHRH/GH release and GH basal secretion.
Nevertheless, a direct involvement of opioid control at the pituitary cannot be
excluded (Villa et al., 1997). Similarly, opioid receptor blocade with naloxone
significantly blunted the GH response to GHRH in postpubertal human males. These
findings indicate that there exists an opioid stimulatory tone on GH secretion (Tomasi
et al., 1998).

In the adult pig, opioid control of GH secretion was studied in primiparous sows that
had been immunized against GRF (1-29) conjugated to human serum albumin (HSA)
or only HSA, to determine changes in GH after naloxone treatment. Naloxone
suppressed GH levels in all sows. In HSA sows, naloxone abolished episodic release
of GH and decreased average but not basal (lowest levels) concentrations of GH. In
sows immunized against GRF-HSA, naloxone decreased average and basal GH levels
but failed to decrease frequency of GH pulses. The authors concluded that opioids
alter concentrations of GH release not only through GRF-dependent but GRF-
independent pathways are also involved (Armstrong et al., 1990).

      -35-

2.0  AIMS AND OBJECTIVES

As the literature review indicates, most of the opioid effects are brought about via the
action of opioids on the central nervous system. Peripheral opioid effects or a direct
effect on pituitary are however also probable. Thus the present project aimed to
evaluate the direct effects of opioids on pituitary LH and GH secretion. To achieve
this, a series of experiments were conducted with the following questions using a pig
pituitary perifusion system.

- Do opioids affect spontaneous LH and GH secretion ?
-      Do opioids affect LHRH-induced LH secretion ?
- Do opioids affect GHRH-induced GH secretion ?
- Are opioid effects on GH secretion modified during LHRH surge ?
-      Are these opioid effects gender- and/or age-dependent ?
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3.0 MATERIALS AND METHODS

3.1    Experimental animals

A total number of 147 female and male Göttingen miniature pigs with ages  254 ±
3.7days (adults), 14 ± 2.4days (piglets) and 109 ± 3days post coitus (fetuses) were
taken from the institute’s experimental farm. The adults were fed twice daily with a
commercial diet (≅ 1.5kg/day). Pregnant animals received a standard diet for pregnant
sows. The piglets were kept with their sows for suckling until slaughter. The fetuses
were obtained from the sows immediately after caesarian section. The experimental
animals were kept under natural lighting condition. The room temperature was
maintained at approximately 22°C and relative humidity of 60%. Data presented on
table 3 indicates the number of animals in the different groups according to age and
gender irrespective of the replicates of the different treatments.

Table 3 : Number of experimental animals according to age and gender

Gender / Group Adults Piglets Fetuses
Males 46 17 13
Females 391 19 13
Total 85 36 26

1= 31 adult females with P4  > 3.5ng/ml (luteal phase) and 8 with P4<3.5ng/ml


3.2  Removal of anterior pituitary tissue

To obtain adenohypophyses (anterior pituitary, AP) from the fetuses, caesarian
sectioning of pregnant sows was carried out under general anaesthesia (Methomidate-
HCL, 500mg/sow, Janssen, Düsseldorf, Germany) and strict hygienic conditions.
Anterior pituitary tissues were removed from the adults and piglets immediately after
slaughter in the slaughter house of the institute.
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Pituitary glands were aseptically removed and immediately introduced into a petri
dish containing solution 2 (see 3.4) within 5-7 minutes of death. The anterior and
posterior lobes were carefully separated after washing with solution 2. The anterior
lobe was cut into small fragments of ≅1mm3 using sterile scalpel blades. The
fragments of adenohypophyses were further washed with solution 2 and transfered
into the perifusion chambers with pasteur pipettes. The weights of the pituitaries were
measured before beginning the perifusion.

3.3  Perifusion system 

The perifusion system was set up as described by Porter (1985) and Porter and Licht
(1985) and as modified by Gracia-Navarro et al., (1991) see scheme 2. The
adenohypophyses tissues to be perifused were placed in small columns fashioned from
1ml disposable plastic syringes (Henke-Sass-Wolf, Tuttlingen, Germany). The
effective volume of each column was 100µl. These columns were placed in  25ml
tubes that were inserted in a warm water bath maintained at 37°C. Each perifusion
chamber (column) contained only fragments from one animal, with ½
adenohypophysis (AP) tissue for adults and piglets and 1 AP for the fetuses. 12
chambers were run simultaneously in parallel at each experiment. All 12 chambers
with AP tissues were attached to a peristaltic pump (Ismatic type IPN 12, Zürich-
Switzerland) that delivered the minimum essential medium (MEM) (solution 1, see
3.4) at a flow rate of 0.1ml/min (6ml/h) and fraction samples were collected at 15
minutes or 5 minutes intervals. Before begin of treatment, tissues were perifused for
about 22-24 hours with medium only to acclimatize the cells and stabilize the basal
secretion of hormones.
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Scheme 2 : Schematic diagram of perifusion system modified after Gracia-Navarro et
al., (1991).

A = Air pump
B = Cold water bath (4°C)
C = Peristaltic pump
D = Warm water bath (37°C)
E = Chamber for pituitary tissue
F = Nylon filter platform
G = Hypodermic needle
H = Rubber stopper
I = Fraction collector 
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3.4  Reagents 

Solution 1 (perifusion medium)

- Minimum Essential Medium (MEM) eagle (Sigma , Munich, cat n° M0643)
composed of 2.2g NaHCO3  and 2.383g HEPES was dissolved in autoclaved bidest
to obtain 1 litre of perifusion solution with pH 7.3 .The medium was filtered into
autoclaved bottles.
- Antibiotics : 100 UI/ml penicillin, 0.25µg/ml amphotericin B, 100µg/ml
streptomycin (Antibiotic/Antimycotic drugs, Sigma n° A 7292) were also dissolved in
20 ml autoclaved bidest. After filtration with membrane filters (milipore type
0.22um), 10 ml of the antibiotic solution was transfered into the 1 litre MEM
perifusion solution and later conserved at 4°c in a refrigerator. Before anterior
pituitaries were perifused, 1g of bovine serum albumin (BSA) was diluted and given
into the perifusion medium.

Solution 2 (extraction and washing medium)

- 100 ml of perifusion solution (solution 1) was measured  and 0.5 ml antibiotic
solution was added into it. 10% BSA was diluted in phosphate buffer saline (PBS)
composed of 0.56g NaH2PO4 .2H2O and 0.85g NaCl at pH 7.4. The solutions were
mixed and stirred with a magnetic stirrer, then covered with parafilm and stored at
4°c. Both the perifusion and extraction/ washing solutions were used within 2 weeks.

 3.5  Experimental design

Following stabilization, the pituitary tissues were perifused for 5 hours. Samples were
collected every 15 minutes for 60 minutes before the onset of opioid treatment.
Immediately thereafter the infusion with one of the following opioids began:
ß-endorphin 5 x 10-9M (ß-endorphin, E0637, Sigma-Aldrich Chemie GmbH,
Steinheim-Germany) ; dalargin 10-6M (D-Ala2-Leu-enkephalin-arg, Bachem,
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Biochemica GmbH; Heidelberg-Germany); naloxone 10-6  M (Naloxone
Hydrochloride, Sigma-Aldrich Co., München-Germany) and concomittant infusion of
naloxone 10-6M and ß-endorphin 10-9M. The perifusion with opioids lasted for180
minutes during which the collection of samples occurred in 15 minutes interval.
At the end of opioid infusion, some pituitaries were stimulated with 10-9M luteinizing
hormone releasing hormone (LHRH, Bachem, Biochemica GmbH, Heidelberg-
Germany) or 10-9M GRF (GHRH, Bachem, Biochemica GmbH, Heidelberg-
Germany) for 5 minutes. After application of LHRH or GRF, samples were collected
for 60 minutes at 5 minutes intervals (see scheme 3). Each sample of 1ml was
centrifuged at 3000g for 10 minutes at 4°c to discard the cellular debris. The
supernatant was then transfered into labelled test tubes and immediately stored at -
20°c until hormone analysis were carried out. Control samples were obtained in which
saline treatment was given into perifusion medium after 1 hour pretreatment period
and later LHRH or GHRH treatments were administered  after 3 hours of sampling.
Data on table 4 show number of animals used for the different treatments as well as
controls.


Table 4: Number of animals for the different treatments.


            Adults            Piglets            Fetuses
Treatments Females Males Females Males Females Males
ß-endorphin + LHRH
     12       8       5       4       4       3
Dalargin +LHRH
       5       6       3       5       2       3
Naloxone + LHRH
     10       8       4       4       4        3
ß-end + Nal + LHRH
       7       6       -        -       -       -
Saline + LHRH
       5       8       7       4       3       4
ß-end + GHRH
       -       5       -        -       -       -
Saline + GHRH
       -       5       -        -       -       -
Total      39     46     19     17     13     13
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Onset of  Opioid infusion    LHRH  or GRF- Stimulation

 Pretreatment
 Period
     

          Sampling interval:                Sampling interval:      Sampling
interval:
        15mins          15mins        5mins

 
 *9:00     *10:00         *13:00       *14:00
              
 
* Local time

        Termination of opioid
infusion

Scheme 3:  Schematic representation of experimental design


3.6.0        Hormone Analysis

3.6.1 Luteinizing Hormone (LH) Analysis


The concentration of LH in the samples was evaluated through a homologous double-
antibody radioimmunoassay (RIA) as described by Pomerantz et al., (1974) and
Ponzilius et al., (1986). The specific antiserum (polyclonal) for porcine LH extracted
from a rabbit was got from UCB-bioproducts, Brüssel, Belgium) and was used in a
dilution of 1: 80000. 100µl of this solution can bind to 30% of the 125I- labelled
porcine LH (tracer). The cross-reactivity of this antiserum with other porcine
hypophyseal hormones is less than 1%. The standards were evaluated in triplicate
whereas the samples underwent double analysis. Pure porcine LH (UCB-bioproducts,
Brüssels, Belgium) with a biological activity of 0.85IU/mg  x NIH st. LH S19 was
used in the standards and the radiolabelling with 125I. The minimum detectable
concentration of LH in the assay was at 0.2ng/ml. The intra- and interassay
coefficients of variation were 3.5 and 6.5 % respectively. The CPM in the standards
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and samples was estimated by an automatic γ-Counter ( LKB- Wallace, 1277 Gamma-
master) and the concentration of LH was done by a RIA calc. computer programm.

3.6.2 Growth Hormone (GH) Analysis

Growth hormone concentration was also measured with a homologous double-
antibody radioimmunoassay that has been modified and validated in our laboratory
(Bauer and Parvizi, 1996). Pure porcine GH utilised for the standards and tracer was
obtained from (UCB-bioproducts, Brüssels, Belgium). The first antibody (Rabbit
antiserum pGH, final dilution 1:100000) and the second antibody (Goat-antiserum-
antirabbit gammaglobulin, final dilution 1:100) were extracted and prepared in our
laboratory. These antibodies (polyclonal) do not show any cross-reactivity with other
pituitary hormones. The intra- and interassay coefficients of variations were 6.5 and
11.5 % respectively.

3.6.3  Progesterone Analysis

Plasma samples obtained from adult females were evaluated for progesterone  (P4) 
level using an enzymimmunoassay validated and modified in our laboratory (Herrler
et al., 1991).The specific antiserum (polyclonal) solution utilised was obtained from
goat and showed high affinity in a concentration of 3µg/ml. The enzyme solution was
made of 2.5% caesin in a buffer solution with pH 7.2 and given at a proportion of 300-
350 µl/ well.The tracer used was HRP-6-progesterone in a concentration of
4µg/ml.The intra- and interassay coefficients of variation were 12.2 and 15.5%
respectively. The cross-reactivity with 17α-hydroxyprogesterone, estradiol and
cortisol were less than 0.1%.  Females with high (P4>3.5ng/ml)  and low (P4
<3.5ng/ml) plasma progesterone levels were grouped and tested separately.
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3.7  Statistical Analysis

The data obtained from the measurements of LH and GH concentrations were
statistically analysed using the “SAS” statistic programm (version 6.08). Firstly, the
absolute mean concentrations of the control samples for the different age and sex
groups were determined. Data were converted to percentage of basal secretion before
averaging to minimize differences between experiments. The absolute mean
concentration of basal secretion for control samples obtained was considered here as
100%. The net percentage increase or decrease of  LH and GH release were calculated
by : ECS – CMCc  * 100%
            CMCc
Where ECS = Evaluated concentration of Sample
      CMCc = Calculated Mean Concentration of control
A positive net percentage value indicated an increase, therefore added to 100%.
A negative net percentage value indicated a decrease, therefore substracted from
100%.
The area under the curves (AUC) for GH and LH profiles were calculated by
substracting basal GH and LH concentrations (mean value) at the pretreatment period
from the posttreatment values. The net values were then summed up to obtain the
AUC. The Students’ t-test was then employed to compare the means of  GH and LH
concentrations in opioid treated and in saline (controls) in the same age and sex
groups at probability level of 5%. To obtain variations in different age groups with the
same treatment, the analysis of variance (ANOVA) one-way was used. P-value less
than 0.05 (P <0.05) was taken as significantly different from controls. Comparison in
different age groups with different treatments was calculated using the one way
ANOVA. The standard errors of means (SEM) are not indicated on the figures to
enable visual clarity of plots.
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4.0 RESULTS

The spontaneous LH and GH release, calculated by the means of samples before the
beginning of treatments in different age groups and gender are shown in table 5.

Table 5 : Mean ± SEM of basal secretion of LH and GH before treatment.
           LH (ng/mg/AP)           GH (ng/mg/AP)
Age / Gender  Males  Females Males Females
Adults 12.92 ±4.2 18.42 ±3.65a
(1)
28.4 ±6.3 32.02 ±5.6
Piglets
 6.81 ±2.3  8.05 ±3.4 25.7 ±3.4 18.6 ±2.1 b
Fetuses 4.05 ±1.35  5.61 ±1.9 63.4 ±15.2  58.3 ±8.7 c (2)

a  indicates a statistical significant difference (P<0.05) in basal secretion of LH                
from adult females compared with males.
b  indicates a statistical significant difference (P<0.05) in basal secretion of GH               
between female and male piglets.
c  indicates a statistical significant difference (P<0.05) in basal secretion of GH                
from fetuses compared with piglets and adults.
(1) indicates a statistical significant difference (P<0.05) in basal secretion of LH        
from adults compared with piglets and fetuses.
(2)  indicates a statistical significant difference (P<0.05) in basal secretion of GH      
from fetuses compared with piglets and adults.

The mean basal secretion of LH was significantly higher in adult females (18.42
±3.65ng/mg/AP) than in adult males (12.92 ±4.2ng/mg/AP). There was no significant
difference in basal secretion of LH between male (6.81 ±2.32ng/mg/AP) and female
piglets (8.05 ±3.4ng/mg/AP) as well as between male (4.05 ±1.35ng/mg/AP) and
female (5.61 ±1.9ng/mg/AP) fetuses. As expected, basal secretion of LH was
significantly higher in the adults as compared with the piglets and fetuses. There was
no significant difference in LH secretion from pituitaries of sows with low (P4<
3.5ng/ml) and high (P4> 3.5ng/ml) plasma progesterone concentrations. Data on basal
secretion of progesterone is not indicated on the above table because the assays were
evaluated only for adult females.

Growth hormone basal secretion was different in the 3 age groups, with fetuses
showing the highest levels in males (63.4 ±15.2ng/mg/AP) and in females (58.3
±8.7ng/mg/AP). The basal secretion from piglet (25.7 ±3.4 ng/mg/AP in males and
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18.6 ±2.1ng/mg/AP in females) and adult pituitaries (28.4 ±6.3ng/mg/AP in males and
32.02 ±5.6ng/mg/AP in females) differed only slightly. A significant gender-
difference  in GH basal secretion was only seen in the piglets, with the males showing
higher  levels (25.7 ±3.4ng/mg/AP) than females (18.6 ± 2.1ng/mg/AP).
              
4.1.0     Opioidergic effects on LH release
4.1.1 Opioidergic effects on LH release in fetuses

The opioid agonist ß-endorphin caused a significant increase (p<0.05) in LH secretion
from both male and female fetal pituitaries (adenohypophyses) when compared to
controls (fig. 1). ß-endorphin-induced increment in LH secretion started 15 minutes
after onset of opioid treatment and lasted for 165 minutes.  There was a significant
sex-difference (p<0.05) in LH secretion from fetal pituitaries, with males showing a
greater response (425 ±20%) than females (275 ±15%) see (table 6 on page 53).
Naloxone and dalargin did not affect LH secretion from both pituitaries of fetal
females and males (fig. 2 & 3). The LH release in response to naloxone reached only
150  ±10% in females and 130 ±15% in male pituitaries. The dalargin-induced LH
release was also marginal reaching 130 ±15% in females and 120 ±10% in male
pituitaries (table 6 on page 53).

4.1.2 Opioidergic effects on LH release in piglets

A high individual variation in response to ß-endorphin was a characteristic reaction in
piglets. The ß-endorphin-induced LH discharge was seen in pituitaries of 3 out of 5
females and 3 out of 4 males. ß-endorphin was found to significantly increase
(P<0.05) LH secretion from both female and male pituitaries of piglets when
compared to controls (fig 4). Increase in LH secretion began 15 minutes after opioid
treatment and lasted for 160 minutes in both pituitaries of females and males. The ß-
endorphin-induced LH secretion attained peak levels of 325 ±35% in males and 175
±15% in females (tab. 6).
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Figure 2: In vitro release of LH from perifused pituitaries of
                fetuses treated with or without dalargin.
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Figure 1: In vitro release of LH from perifused pituitaries of fetuses
              treated with or without beta-endorphin.
             *P<0.05  shows a statistically significant difference between treated
              males and females and controls at period indicated with arrows.
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Figure 3: In vitro release of LH from perifused pituitaries of
               fetuses treated with or without naloxone.
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Figure 4: In vitro release of LH from perifused pituitaries of piglets treated with
              or without beta-endorphin. *P<0.05  shows a statistically significant
              difference between treated males and females and controls at
              period indicated with arrows.
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Figure 5: In vitro release of LH from perifused pituitaries of
                piglets treated with or without dalargin.
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Figure 6: In vitro release of LH from perifused pituitaries of
               piglets treated with or without naloxone.
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However, the total LH increase found in piglets was significantly lower than that seen
in fetal pituitaries.

Naloxone and dalargin did not show any effects on LH secretion in pituitaries of both
female and male piglets. The naloxone-induced LH release reached 125 ±20% in
pituitaries of females and 125 ±40% in males. The LH release in response to dalargin
attained 135 ±15% in pituitaries of males and 115 ±10% in females (table 6).
                        
4.1.3  Opioidergic effects on LH release in adults

ß-endorphin elicited a significant increase (p<0.05) in LH release in pituitaries of
adult females and males as compared to controls. In adult male pituitaries LH
secretion reached a peak level ( highest concentration of LH measured after the
administration of opioid) of 245 ±45% recorded 90 minutes after opioid treatment
(fig. 7). LH secretion in adult female pituitaries attained a peak level of 160 ±15%
recorded 60 minutes after opioid treatment in females with plasma progesterone level
higher than 3.5ng/ml (see figure 9). The LH discharge in response to ß-endorphin
treatment was significantly higher (p<0.05) in adult males than in adult females. The
net increase in LH secretion was higher in adult pituitaries than in fetuses and piglets
when their area under the curves (AUC) were compared.

Again, naloxone and dalargin exerted no significant actions on LH secretion in both
pituitaries of adult females and males (fig. 8, 10 & 11). However, a slight but not
significant decline in LH release occurred towards the end of the sampling period in
response to naloxone in females with low levels (P < 3.5ng/ml) of circulating
progesterone (fig.11, page 52). Interestingly, neither in adult males nor in adult
females did naloxone antagonize ß-endorphin-mediated LH release (fig.12, page 52).
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Figure 7  :  In  vitro  release of LH  from  perifused pituitaries of adult
                males treated with  or without beta-endorphin.
                *P<0.05  shows a statistically significant difference between
                treated males and controls at period indicated with  arrows.
Figure 8  : In  vitro  release of LH  from perifused pituitaries of adult males
                   treated with  or without dalargin or naloxone.
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Figure 9 : In vitro release of LH from perifused pituitaries of adult females treated with or without
               beta-endorphin. *P<0.05  shows a statistically significant difference between treated
               females with high (P4>3.5ng/ml) and low (P<3.5ng/ml) or controls (P=3.5ng/ml)
               progesterone levels at period indicated with arrows.
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Figure 10 : In vitro release of LH from perifused pituitaries of
                   adult females treated with or without dalargin.
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Figure 11 : In vitro release of LH from perifused pituitaries of adult
                   females treated with or without naloxone.
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Figure 12 : In vitro release of LH from perifused pituitaries of adult males and females
                 treated with or without naloxone + ß-endorphin.*P<0.05  shows a statistically
                 significant difference in treated males and females and controls at
                 period indicated with arrows.
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  Table 6 : Opioid-induced LH release from pituitaries of females and males in all age groups.


*  indicates a statistical significant (P<0.05) difference compared to corresponding controls considered as 100%
a, b and c  indicate a statistical significant (P<0.05) difference between ß-endorphin treated males vs. females.


































Age group Fetuses Piglets Adults
Gender/ Parameter Females Males Females Males Females Males
% Peak level of
ß-endorphin-induced
LH release
*
275  ±15%
(n=4)
* (a)
425  ±  20 %
(n=3)
*
175  ±  15%
(n=5)
* (b)
325  ±35%
(n=4)
*
160  ±15%
(n=9)
*(c)
245  ±45%
(n=8)
% Peak level of
naloxone-induced LH
release

150  ±10%
(n=4)

130  ±15%
(n=3)

125  ±20%
(n=4)

125  ±40%
(n=4)

135  ±10%
(n=7)

130 ±25%
(n=8)
% Peak level of
dalargin-induced LH
release

130  ±15%
(n=2)

120  ±10%
(n=3)

115  ±10%
(n=3)

135  ±15%
(n=5)

105  ±15%
(n=3)

135 ±%
(n=6)
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4.2.0     Opioid-LHRH interaction and LH release

The opioidergic interaction with LHRH on LH release was measured in pituitaries
from female and male (fetuses and piglets) and adult females. Pituitaries received
LHRH (10-9M) stimulation for a period of 5 minutes beginning 180 minutes after
opioid treatment and samples were collected at 5 minutes interval for an experimental
period of one hour.

4.2.1   Fetuses

Fetal female but not male pituitaries pretreated with ß-endorphin showed a reduction
in LHRH-induced LH release that lasted for 10 minutes after LHRH-stimulation
when compared to time and age-matched saline pretreated controls see  (fig. 13). There
was an impairment of LHRH-induced LH release in naloxone and dalargin pretreated
pituitaries of fetal females and males beginning 30 minutes after  LHRH-stimulation
(fig. 14 & 15). These effects were however not statistically significant when compared
to controls.

4.2.2     Piglets

There was a 300 % and 205 % enhancement in LH secretion 30 minutes after the start
of LHRH challenge in pituitaries of female and male control piglets respectively (fig.
16).
It is interesting to note that the peak level of LH release from pituitaries of male
piglets pretreated with ß-endorphin was significantly (p<0.05) higher than that caused
by LHRH stimulation in the control group (325 % vs 225 %) respectively. Unlike in
fetal and adult female pituitaries where ß-endorphin pretreatment resulted to a
blockade in LHRH-induced LH release, female piglets showed no effect in the
LHRH-induced LH release in ß-endorphin pretreated pituitaries compared to saline
pretreated controls.
Pretreatments with naloxone and dalargin also did not modify the LHRH-induced LH
release in both pituitaries of female and male piglets (figure 17 & 18).
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Figure 13: In vitro release of LH from perifused pituitaries of fetuses
                after beta-endorphin pretreatment and later LHRH administration.
            a   shows a statistically significant difference between treated female
                 and control at period indicated with line.
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Figure 14: In vitro release of LH from perifused pituitaries of fetuses
                after dalargin pretreatment and later LHRH administration.
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Figure 15: In vitro release of LH from perifused pituitaries of fetuses
              after naloxone pretreatment and later LHRH administration.
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    Figure 16: In vitro release of LH from perifused pituitaries of piglets after
                     beta-endorphin pretreatment and later LHRH administration.
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Figure 17: In vitro release of LH from perifused pituitaries of piglets
                after dalargin pretreatment and later LHRH administration.
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Figure 18: In vitro release of LH from perifused pituitaries of piglets
                after naloxone pretreatment and later LHRH administration.
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Figure 19 : In vitro release LH from perifused pituitaries of adult females after
              pretreatment with different opioids and later LHRH administration.
             *P<0.05 shows a statistically significant difference between beta-endorphin
             pretreated females compared to saline pretreated controls at period
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4.2.3  Adult females

In adult females, LHRH stimulation caused as expected a significant increase
(p< 0.05) in LH release in adult female pituitaries. The LH peak level reached 455 %
of basal levels within 20 minutes after LHRH stimulation  in saline pretreated controls
(fig.19, page 58). On the otherhand ß-endorphin pretreated pituitaries did not show
any stimulatory tone on LH secretion after LHRH application. The peak level of
LHRH-induced LH release attained only 120% in ß-endorphin pretreated pituitaries
whereas the corresponding control level at the same time was 300% compared to ß-
endorphin treated pituitaries.
Pituitaries pretreated with dalargin and naloxone tended to show an impairment of
LHRH-induced LH release as compared to saline controls. But this impairment was
not statistically significant (P>0.05).

4.3.0  Opioidergic effects on GH secretion

4.3.1 Opioidergic effects on GH secretion in fetuses

Spontaneous GH secretion from pituitaries of female and male fetuses can be seen on
fig 20. Treatment with naloxone  did not appear to influence the basal GH secretion
from pituitaries of fetal females and males. Growth hormone secretion from pituitaries
of  fetal males was slightly higher (but not significant) when compared to fetal
females as calculated from AUC (fig. 20).
             
The opiate agonist ß-endorphin caused a significant increase (p< 0.05) in GH
secretion from pituitaries of male fetuses beginning 30 minutes after treatment and
lasting for 90 minutes (fig. 21). Although, there was an apparent increase in GH
concentration from pituitaries of fetal females , this was not statistically significant
(p>0.05) thus indicating a sex differential effect of ß-endorphin on GH secretion in
fetuses. The opioid agonist, dalargin showed no effect on GH release from pituitaries
of fetal females and males when compared to saline controls (fig. 22).
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Figure 20 : In vitro secretion of GH from perifused pituitaries of
                  fetuses with or without naloxone treatment.
Figure 21 : In vitro secretion of GH from perifused pituitaries of
                 fetuses with or without beta-endorphin treatment.
                 *P<0.05  shows a statistically significant difference between
                  treated males and controls at period indicated with arrows.
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Figure 22 : In vitro secretion of GH from perifused pituitaries of
                   fetuses with or without dalargin treatment.
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4.3.2 Opioidergic effects on GH secretion in piglets

In male piglets, the opiate antagonist naloxone elicited a decrease in spontaneous GH
secretion after one hour of treatment, but this decline was not statistically significant.
On the otherhand, female pituitaries showed a significant (p<0.05) increase in GH
secretion (680 ±75%) see (table 7, page 67) after two hours of naloxone treatment (fig.
23). ß-endorphin and dalargin showed no effects on the spontaneous GH release from
pituitaries of both female and male piglets throughout the treatment period (fig. 24 &
25).

4.3.3 Opioidergic effects on GH secretion in adults

Spontaneous GH secretion from pituitaries of adult females and males is illustrated in
figure 26. Treatment of both pituitaries of adult females and males with the opiate
antagonist naloxone did not show any significant effects on the spontaneous secretion
of GH as compared to controls (fig. 26). The sporadic secretory pattern of GH was
maintained  in both sexes. The concentration of GH secreted by adult males was
higher than in  females as seen from AUC.

The opiate agonists, dalargin and  beta-endorphin both significantly (p<0.05)
increased the secretion of GH from adult male adenohypophyses from 10 minutes
after  treatment until 90 minutes thereafter. Dalargin and  ß-endorphin caused an
increment in spontaneous GH secretion reaching 610 % and 660 % respectively (fig.
27 & 28). Contrary, the pituitaries from adult females were not affected after dalargin
and ß-endorphin administration.

The concomitant administration of naloxone and ß-endorphin to adult male pituitaries
showed a drastic decline in GH levels indicating that naloxone could antagonize
ß-endorphin-mediated GH increase in adult males (fig. 29). Whereas in adult female
pituitaries, naloxone apparently does not exhibit effect.
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Figure 23 : In vitro secretion of GH from perifused pituitaries of
                 piglets treated with or without naloxone.
              a shows a statistically significant difference between treated
                 females and controls at period indicated with line.
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Figure 24 : In vitro secretion of GH from perifused pituitaries of
                  piglets with or without beta-endorphin treatment.
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Figure 25 : In vitro secretion of GH from perifused pituitaries of
                   piglets with or without dalargin treatment.
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Figure 26 : In vitro secretion of GH from perifused pituitaries of adults
                   with or without naloxone treatment.
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Figure 27 : In vitro secretion of GH from perifused pituitaries of adults
               with or without dalargin treatment. *(P<0.05) shows a statistically
              significant difference between adult males and controls at period
              indicated with arrows.
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Figure 28 : In vitro secretion of GH from perifused pituitaries of adults with or
                without beta-endorphin treatment. * P<0.05)  shows a statistically
                significant difference between adult males and controls at period
                indicated with arrows.
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Figure 29 : In vitro secretion of GH from perifused pituitaries of adults
                   with or without beta-endorphin + naloxone treatment.
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Table 7 : Opioid-induced GH release in both sexes of all age groups

Age group            Fetuses            Piglets          Adults
Gender/ Parameter Females
( n=9 )
Males
( n=10 )
Females
( n=12 )
Males
( n=13 )
Females
( n=19 )
Males
( n=22 )
%Peak level of ß-endorphin-
induced GH secretion

405 ±110%
a
625 ±125%

380 ±65%

275 ±35%

680 ±75%
b
660 ±65%
%Peak level of naloxone-
induced GH secretion

400 ±45%

475 ±55%
c
680 ±120%

350 ±50%

310 ±45%

520 ±105%
%Peak level of dalargin-
induced GH secretion

420 ±20%

420 ±25%

250 ±35%

290 ±35%

380 ±20%
d
610 ±95%

a   indicates a statistical significant (P<0.05) difference between ß-endorphin treated        
pituitaries of fetal males and controls.
b  indicates a statistical significant (P<0.05) difference between ß-endorphin treated        
pituitaries of adult males and controls.
c   indicates a statistical significant (P<0.05) difference between naloxone treated              
pituitaries of female piglets and controls.
d  indicates a statistical significant (P<0.05) difference between dalargin treated                
pituitaries of adult males and controls.

4.4  Opioid-LHRH interaction on GH secretion

Interaction between opioids and LHRH on the secretion of GH was measured in adult
females and males exclusively. GH secretion from pituitaries of adult females (both
high and low plasma concentrations of progesterone) pretreated with naloxone
decreased significantly (p<0.05) after LHRH application. Whereas there  was no
alteration in GH levels after LHRH application in pituitaries of adult males pretreated
with naloxone compared to controls (fig. 30). 
The dalargin-induced GH increment in adult males was attenuated after LHRH
stimulation when compared with saline pretreated controls. Pretreatment with dalargin
did not alter GH secretion after LHRH administration in pituitaries of adult females
(figure 31).
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Figure 30: In vitro secretion of GH from perifused pituitaries of adults after
                 naloxone pretreatment and later LHRH administration.
            b    shows a statistically significant difference (P<0.05)  between
                 adult females and control at period indicated with line.
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Figure 31: In vitro secretion of GH from perifused pituitaries of adults after
                 dalargin pretreatment and later LHRH administration.
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Figure 32: In vitro secretion of GH from perifused pituitaries of adults after beta-endorphin
                 pretreatment and later LHRH administration.
            c   shows a statistically significant difference (P<0.05) between adult females
                 and control at period indicated with the line
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Figure 33: In vitro secretion of GH from perifused pituitaries of adults after
beta-endorphin and naloxone pretreatment and later LHRH administration.
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It was observed that GH secretion decreased significantly (p<0.05) after LHRH
administration in pituitaries of adult females pretreated with ß-endorphin. The decline
in GH secretion occurred approximately 30 minutes after stimulation. Whereas GH
levels in pituitaries of adult males pretreated with ß-endorphin were unaffected by
LHRH stimulation (fig. 32). Simultaneous pre-administration of naloxone and beta-
endorphin did not appear to change the pattern of GH secretion observed after LHRH
challenge  in beta-endorphin pretreated pituitaries of females and males (fig. 33).

4.5            Opioid-GHRH interaction on GH secretion

The interaction of opioids (ß-endorphin) and GHRH was tested only in pituitaries of
adult males.  The pretreatment with ß-endorphin did not appear to influence GHRH-
induced GH secretion. There was no significant difference (p> 0.05) in GH secretion
after GHRH-stimulation in pituitaries pretreated with ß-endorphin compared with the
saline pretreated controls. There was no interaction between GHRH and opioids at the
pituitary (fig. 34).
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Fig. 34: In vitro release of GH from perifused pituitaries of adult males after
            beta-endorphin treatment and subsequent GHRH administration.
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5.0  DISCUSSION

There are several routes through which endogenous opioids might act to exert their
effects.  Regarding the regulation of hormone secretion the route via the CNS seems
to be the major one. But there is  considerable evidence that opiates can exert direct
effects on the pituitary  to modify the regulation of LH and GH. This route is however
less explored.
The present study was therefore geared at verifying the effects of opioids on LH and
GH release activity at the pituitary level in male and female pigs at different stages of
development.
ß-endorphin enhanced LH release in both pituitaries of fetal females and males in
vitro. Interestingly, LH secretion from pituitaries of fetal males was higher than from
female ones. Although the basal pituitary LH release has been shown to be
significantly lower in male than in female fetuses (Elsaesser et al., 1988), this
difference was evident in the present study tendentiously. This indicates that
pituitaries of fetal males are presumably more sensitive to ß-endorphin than
adenohypophyses of fetal females to secrete LH. The ß-endorphin-mediated
stimulatory effect on LH secretion in the pituitary of the fetal pig  has not yet been
mentioned before. Comparative studies with other species at the fetal stage are
lacking. But related in vivo studies in the fetal pig by Behrens-Herrler and Parvizi
(1992) revealed that single and repeated administrations of the opioid agonist,
morphine decreased LH in both female and male fetal pigs.
The opioid antagonist naloxone did not alter LH secretion in fetal pituitaries of both
females and males. Supportive data has been reported by Behrens-Herrler and Parvizi
(1992), where a single injection of naloxone was not effective in modifying LH
release from female and male fetal pigs. However, an inhibitory naloxone effect
could be induced with daily naloxone injections in male fetuses but not in females. In
contrast to the above findings, in the chronic catheterized fetal lamb, naloxone
induced a prompt increment in plasma LH levels (Cuttler et al., 1985). The naloxone
effector mechanism on LH release in the fetal pig is assumed to be quiescent and
probably becomes operative in the pig weeks after birth (Parvizi et al., 1995).
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The leu-enkephalin opioid agonist, dalargin did not modify LH release from fetal
pituitaries. This opioid analogue was used because it has been shown to have effects
on local peripheral target tissues and its effects are not necessarily brought about
through the CNS (Il’inskii et al., 1987). Dalargin  has a higher affinity to the δ-opioid
receptor (Pencheva, 1996) but the δ-receptor is virtually absent in the fetal pig (Kahle
and Parvizi, 1993). The ineffectiveness of dalargin to influence LH secretion could be
a result of absence of delta receptors in the fetal pig. The absence of δ-opioid
receptors, however, cannot be solely responsible for the lack of dalargin effect, since
dalargin has no effects in piglets (see below) where δ-opioid receptors are detectable
(Kahle, 1993).
Similarly in the piglets, ß-endorphin treatment evoked an increase in LH secretion
from pituitaries of both females and males. Again, naloxone and dalargin showed no
effects. Naloxone also failed to influence LH secretion in intact and castrated
immature male pigs (Trudeau et al., 1988), in heifers (Gazal and Anderson, 1995) and
in prepubescent male rats (Cicero et al., 1993). These observations led to the
suggestion that naloxone does not alter LH secretion until after puberty. It is worthy to
mention that heifers are not necessarily a good example for immature female animals,
because naloxone is also not effective in inducing any changes in LH release in adult
cattles with exception of suckled cows.    
Interestingly, the response of adult pituitaries to ß-endorphin treatments was an
increment in LH discharge into the medium. The effect of ß-endorphin in females was
only significant when the pituitaries were removed at a period of cycle with high
progesterone (P4>3.5 ng/ml) levels. It is certainly accepted that female animals with
plasma progesterone concentrations greater than 3.5 ng/ml are well in the luteal phase
of the cycle. However, animals with P4<3.5 ng/ml cannot be considered to be
homogenous concerning their pituitary LH release and ovarian steroid hormone
background. They could be in a phase of the cycle immediately after luteolysis,
before, in or during the LH peak or shortly after ovulation. Again the pituitaries of
males exhibited a more profound response than females, despite the significantly
higher basal LH secretion from pituitaries of females. This more sensitive reaction of
pituitaries of males throughout the different stages of development has not been
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studied and thus not described previously. It could be a testosterone-dependent event.
However, it seems to be a yes or no response and not neccessarily a dose-dependent
one. ß-endorphin stimulation of pituitary LH release in vitro has been also
documented in the sheep where human ß-endorphin and γ-endorphin elevated LH
secretion in perifused pituitaries 30 minutes after exposure (Matteri and Moberg
1985).
A report by Barb et al., (1990) also disclosed that 10-9M ß-endorphin significantly
augmented LH secretion in mature gilts pituitary cell cultures. Whereas lower 10-10M
or higher 10-7M doses of ß-endorphin failed to alter LH release after 4 hours exposure.
In contrast, ß-endorphin caused a reduction of LH secretion when applied to murine
(Lucinda and Franco, 1985)  and  bovine (Chao et al., 1986) pituitary cells.
The opioid antagonist, naloxone failed to modify LH secretion. This is somehow to be
expected because naloxone was given in the absence of opioid agonist and naloxone
as a pure opioid antagonist should not have any intrinsic effect. Strange is that
naloxone could not inhibit the effect of ß-endorphin. This could be due to the mode of
application. In the present study, naloxone and ß-endorphin were applied
concomitantly. The better mode would have been a naloxone treatment preceding the
ß-endorphin challenge. Nevertheless, these findings are confirmed by Matteri and
Moberg, 1985 and Cicero et al., 1979 who also could not show any effects of
naloxone on sheep and rat pituitary cultures, respectively . Controversially, Barb et al.,
1990 reported a stimulatory action of naloxone on pig pituitary cells. The discrepancy
between this and the present results could be due to differences in the methodological
approach. Barb et al. used a static cell culture and incubated the cells for a period of
over 24 hrs with naloxone. This long-term exposure could have evoked some
naloxone effects not attributable to the opioids (Kahle, 1993).
Dalargin, the leu-enkephalin analogue used in the present study did not alter LH
secretion from pituitaries of females and males. However, it does decrease LH
secretion when microinjected into the pig brain in vivo (Anderheiden & Parvizi,
1996). The endogenous opioid, met-enkephalin and the synthetic D-Phe2-met-
enkephalin inhibited LH release from cultured bovine pituitary cells (Chao et al.,
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1986) and rat pituitaries (Dragatsis et al., 1995) respectively. Met-enkephalin binds to
the µ  and δ-receptors with almost the same affinity (Akil et  al., 1988) but its analogue
dalargin, seems to have a higher affinity to delta receptors and may only weakly bind
to µ-receptors (Pencheva, 1996). At the adenohypophyses, mu-opioid receptors are
more abundant than the delta receptors (Mansour et al., 1988). The inability of
dalargin to act directly at the pituitary level suggests that opioidergic control of LH at
the adenohypophysis may be predominantly mediated through mu-opioid receptors.
This study was also aimed at determining if opioids could modify LHRH-induced LH
secretion at the pituitary level. Generally, LHRH has a stimulatory effect on LH
release that may reach several folds compared to the basal secretion. However the
LHRH-induced LH increment depends on the dose applied and other physiological
conditions of the animal or tissue utilised for the experimental study. Barb et al.,
(1990) revealed that 10-9, 10-8, 10-7  M GnRH increased LH secretion 140%, 210% and
250% respectively in pituitary cell culture in vitro. Results of this study indicated that
ß-endorphin pretreatment caused an attenuation of LHRH-induced release of LH in
pituitaries of fetal and adult females with higher peripheral progesterone (P4)
concentrations. Whereas  the LHRH-induced LH secretion was rather impaired but not
significantly in pituitaries of female and male piglets pretreated with ß-endorphin. The
difference seen in LH response of piglets to ß-endorphin pretreatment and later LHRH
stimulation when compared to fetal and adult pituitaries, could be related to lower
progesterone concentration. It is well known that before puberty, neonates and
prepubescents possess relatively low concentrations of circulating steriod hormones,
whereas fetuses receive highly rich steriodal blood from their mothers through the
placental vascular complex into the fetal system (Ponzilius et al., 1986). Results of in
vitro  studies carried out by Sanchez-Franco and Cacicedo (1983), indicated that
gonadotropin releasing hormone stimulatory activity on LH release was blocked by
beta-endorphin in male rat pituitary cells. The intra-pituitary physiological
concentration of beta-endorphin in the pig is estimated to be 3-5 ×  10-9  M (Symth and
Zarkarian, 1980) and this corresponds to the experimental dose employed thus
rejecting the possibility of using an inappropriate dose.
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A plausible explanation of LHRH-induced LH secretion observed after ß-endorphin
could be attributable to a pituitary maximal secretory capacity. It is possible that once
the gonadotrophs responded to beta-endorphin pretreatment with maximal secretory
LH levels, no further release could be achieved with any other LH stimulant, thus
lowered LH response was observed. And of course another possibility is that ß-
endorphin counteracts with LHRH through so far unexplored routes, to control LH
release. It is here to emphasize that the inhibitory action of ß-endorphin on LH
secretion is the most often observed effect of the opioids on gonadotropin secretion in
vivo (Parvizi et al., 1993).
       
Pretreatments with naloxone and dalargin manifested no effects on LHRH-induced
LH discharge in fetuses and piglets.  Comparative studies on the interaction of opioids
and LHRH on LH release at the pituitary in fetuses and postnatals are not available.
Having in mind that both naloxone and dalargin did not alter spontaneous LH
secretion from pituitaries of fetuses and piglets, one might carefully claim that the
opioid receptor activation mechanism mediating these effects is not fully developed or
depends on other non-opioid physiological factors involved in the regulation of LH
secretion in fetal and postnatal pig pituitary. However, the lack of an opioidergic tonus
on LH secretion at the pituitary level in the young animal is most feasible. On the
otherhand, pretreatment with naloxone and dalargin impaired the LHRH induced LH
release from pituitaries of adult females but this was not statistically significant. A
comparative study conducted by Chao et al., (1986) demonstrated that simultaneous
addition of naloxone and LHRH in bovine pituitary cell culture resulted to a non-
significant decrease in LH secretion when compared to LH levels after LHRH alone.
The authors concluded that naloxone does not affect LHRH-induced LH discharge
from bovine pituitary cells. Furthermore, Delitala et al., (1981) also reported that
naloxone showed no effects on LHRH-induced LH release in man. As mentioned
above, the pretreatment with dalargin, an enkephalin analogue only slightly decreased
LHRH-induced LH release. It is worthy  to note that dalargin was not effective in
altering spontaneous LH secretion in this study. Similarly, met-enkephalin did not
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affect basal in vitro LH secretion in ovine pituitary cell culture (Matteri and Moberg,
1985). In another in vitro study, leu-enkephalin enhanced gonadotropin
responsiveness to LHRH (May et al., 1979). The discrepancies between the data could
be due to the species difference and specificity of the substances used. Leu- and met-
enkephalin have been shown to have different effects on LH secretion in the pig
(Parvizi, 1989).
This study concurrently soughted to determine if opiates could influence GH secretion
directly at the pituitary level. It is hypothesized that opioid peptide stimulation of
pituitary GH secretion is mediated through hypothalamic GHRH (Wehrenberg et al.,
1985; Armstrong et al.,1990) and an opioidergic inhibition of somatostatin is also
possible (Delitala et al., 1989). Results of the present study indicate that, ß-endorphin
caused a significant increase in GH secretion from male but not from  female fetal
pituitaries. Comparative in vivo studies were carried out on chronically catheterized
fetuses using morphine. Chronic treatment over 3-4 days with daily injections of
morphine were necessary to prime the brain/ pituitary to response to GH, while single
injection (one day of treatment) had no effects (Parvizi et al., 1995). In the fetal pig
like other species, somatotrophs secrete extremely high concentrations of GH, (see
Bauer, 1992). The reason for a sex-differentiated GH  response to ß-endorphin is not
fully understood. It is, however, worthmentioning that male fetuses have significantly
higher plasma GH levels (Bauer and Parvizi, 1996) and pituitary GH gene expression
(Granz et al., 1997) than their age-matched females. But blocking opioid receptors
with naloxone showed no effects on GH secretion from both female and male fetal
pituitaries in this study. This is in line with results of Parvizi et al., (1995) who
revealed that the opioid antagonist naltrexone had no effects on GH secretion in fetal
pigs. This indicates once more that the opioidergic system controling pituitary
hormone secretion is not fully functioning before birth.
In piglets, naloxone treatment caused a sex-differentiated response. The females
showed a significant increase in basal GH secretion after 2 hours of exposure to
naloxone. An earlier report of Trudeau et al.,(1988) disclosed that treatment with
naloxone did not alter GH secretion in 6 weeks old male pigs. Similarly, blocking
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opioid receptors with naltrexone did not alter GH secretion in piglets (Parvizi et al.,
1995).
Both dalargin and beta-endorphin showed no effects on GH secretion from pituitaries
of both female and male piglets. But Trudeau et al.(1988) reported an increment in
GH secretion in 6 weeks old male pigs after morphine treatment, while Armstrong et
al.,(1993) also revealed an elevation in serum GH release in hypogonadal gilts.
Similarly, morphine caused GH increments in postnatal pigs after 16 days but not
before (Parvizi et al., 1995). It must be noted here that the experimental animals of the
above-mentioned studies and the present one were not age-matched. The present study
used  two weeks old piglets whereas the previous studies used older animals. The
failure of these opioids to exert effects on pituitary GH may not only be due to the
difference in experimental methods but also the age difference of experimental
animals. The age-dependency of opioidergic GH secretion seems to be crucial (for
review see Rettmer, 1994).

In adults, the opiate antagonist naloxone had no effect on basal secretion of GH from
the pituitaries of both female and male pigs. These findings are in conformity with
earlier reports by Pfeiffer and Herz (1984), Trudeau et al., (1988) and later  Armstrong
et al., (1993) who observed no opioidergic control on basal secretion of GH using an
opioid  antagonist. In contrast to the above findings, naloxone attenuated GH
concentrations in mature pigs (Barb et al., 1992). In addition, naloxone also reduced
GH levels in lactating sows that were either immunized against GRF or non-
immunized sows (Armstrong et al., 1990a). Because naloxone decreased GH secretion
in both GRF-immunized and non-immunized sows, immunization against GRF cannot
be the sole reason for the decrement in GH levels in these sows. This suggest that
other intrinsic factors associated to the physiological state (lactation) of  the sows
were involved in decreasing GH levels after naloxone treatment. The elevated levels
of GH during lactation is presumed to be mediated by endogenous opioids (Armstrong
et al., 1990b). Thus the inability of naloxone to alter GH secretion in the present study
could be attributable to absence of these physiological intrinsic factors  in vitro.
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On the otherhand, dalargin and ß-endorphin treated pituitaries of adult males but not
female pituitaries showed a marked increase in GH basal levels. This observation is in
line with several reports suggesting that opioid agonists cause increases in GH
secretion in heifers (Leshin et al., 1990; Johnson et al.,1993 ) in wethers (Armstrong
and Spears,1991) in rats (Eason et al.,1996) in pigs (Barb et al., 1992) and in human
(Schulte et al.,1993). The sex-differentiated effects of opioids on GH secretion has not
been studied in other species. The effect is probably steriod-dependent, however, the
present study does not present any direct evidence for this dependency.

GHRH induced a GH discharge from pituitaries of males comparable to that published
previously (Elsaesser et al., 1996). Interestingly, ß-endorphin pretreatment
potentiated, although not significantly, the effect of GHRH on GH secretion from
pituitaries of adult males. Most interesting is the observation that, application of
LHRH to pituitaries pretreated with ß-endorphin and naloxone showed a significant
decrement in GH secretion in females but not in males. Earlier studies have shown
that treatment with gonadal steriods that cause a surge in LH blunt the stimulatory
effect of morphine on GH release in female  rats (Singh et al., 1992). Looking at the
experimental design, one might assume that, challenge of pituitaries with LHRH
mimicks the physiological condition seen around a preovulatory surge in LH mediated
by LHRH in vivo. Several laboratories have revealed that the opioid receptor number
and naloxone binding are reduced at periods of steriod-induced LH hypersecretion
(Jacobsen et al., 1989; Weiland et al., 1990). Hence the decrement in GH release is
presumed to be a result of suppression of opioid receptor number and activity.
    
The findings of the present study indicate that effects of opioids on spontaneous LH
and GH could be seen at the pituitary level and these effects are sex-, age- and steroid-
dependent. Furthermore, LHRH-induced LH secretion could be opioid-dependent. But
endogenous opioids could exert only minor effects on GHRH-induced GH secretion at
the adenohypophyses in the pig.
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6.0   SUMMARY AND CONCLUSION

• Opioidergic effects on LH secretion

(i) ß-endorphin treatment showed a significant increase in LH release from
pituitaries of fetal, neonatal and adult pigs. However, in adult females significant
levels were measured only from pituitaries of sows with high progesterone levels.
Interestingly, pituitaries of males released significantly higher LH levels in response
to ß-endorphin than females in all age groups.
(ii) Naloxone and Dalargin treatments showed no effects on LH secretion from
pituitaries of  both  male and female fetal, neonatal and adult pigs. Blocking  opioid
receptors with naloxone to increase LH secretion is particularly conventional in in
vivo  studies in adults but not in in vitro studies. In fetal and neonatal pigs, opioid
blockade is less effective in altering LH release. The lack of delta opioid receptors and
prematurity of the opioid system in fetal and neonatal pigs partly accounts for the
inability of dalargin and naloxone to alter LH secretion.
(iii)  Naloxone did not antagonize the ß-endorphin-induced LH release neither from
adenohypophyses of adult males nor adult females when administered concomitantly.
Antagonism might have been observed if naloxone treatment preceded ß-endorphin
treatment.

•  Interaction of opioid and LHRH in LH release

(i) ß-endorphin blocked significantly the LHRH-induced LH release in pituitaries
of  adult females with high progesterone (P>3.5ng/ml) concentration. Similar results
were obtained in fetal pituitaries but in piglets, ß-endorphin only impaired (not
significant) the LHRH- induced LH discharge. This observation suggests that the
steriodal milieu plays a fundamental role in gonadotropic releasing hormonal
influence on opioidergic modulated release of luteinizing hormone in the pig.
(ii) Naloxone and Dalargin impaired (not significant) the LHRH-induced LH
release in pituitaries of both adult females and males. Meanwhile pretreatment with
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naloxone and dalargin had no effects on LHRH-induced LH release in piglets and
fetuses. The similarity in fetal and adult pituitaries response to ß-endorphin
pretreatment and  subsequent stimulation with LHRH on LH release suggest a steriod
hormonal influence of luteinizing hormone at the pig pituitary.

•   Opioidergic effects on GH Secretion

(i) ß-endorphin and dalargin treatment caused marked increases in GH secretion in
adenohypophyses of fetal and adult males but not females, whereas both pituitaries of
female and male piglets showed no effects on GH release.
(ii) Naloxone had no gender-related effect on GH secretion in pituitaries of fetuses
and adults, whereas in piglets there was a sex-differentiated response with males
showing a non-significant decrease and females a significant increase in GH secretion.
This observation suggest that a sex-differentiated opioidergic tonus participates in the
control mechanism of GH secretion at the pituitary level.
(iii) Concomitant administration of naloxone and ß-endorphin attenuated the
ß-endorphinergic-induced increment of GH secretion seen in adult males.
It could be concluded that opioid control of GH secretion is sex-, age- and possibly
steroid-dependent.

•  Interaction of opioid and LHRH  in GH secretion

(i) Pretreatment of adenohypophyses with naloxone and ß-endorphin showed a
marked decrease in GH secretion after LHRH treatment in females (unlike in their
male counterparts that responded with increased GH secretion after ß-endorphin
administration) as compared to saline pretreated controls.
(ii) Dalargin pretreated adenohypophyses did not show any effect on GH secretion
after LHRH administration in female but attenuated GH secretion in adult male
pituitaries. The interaction of opioids and LHRH in GH secretion does not show any
clear cut pattern in pituitaries of females and males. It rather suggests a probable
dependency on the specific substance in action.
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•   Interaction of opioid and GHRH in GH secretion

Preadministration of ß-endorphin and subsequent stimulation with GHRH showed a
non-significant increase in GHRH-induced GH secretion when compared to saline
pretreated controls. These results indicate that opioids exert a stimulatory tone on
basal GH secretion but play a minor role in GHRH-induced GH release in the pig
pituitary.

The discordance in findings of this present study as compared to previous reports
could be attributed to differences in methodological approaches, animal species and
physiological state of the experimental animal. However, direct opioid control of LH
and GH at the pituitary level is evident and the response is age-, sex- and steroid-
dependent. Furthermore, LHRH-induced LH secretion could be opioid dependent but
GHRH-induced GH discharge may only be slightly opioid-dependent in the pig
pituitary.
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7.0 LIST OF SCHEMES

1- Schematic representation of the primary structures of the three precursor genes for
the three largest opioid families and some of their opioid derivatives, modified after
Cox (1982), Schulz and Ehrenreich (1985) Kahle (1993).

2- Schematic diagram of Perifusion system  modified after Gracia-Navarro et al.,
(1991).
3- Schematic representation of experimental design
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without beta-endorphin.
10- In vitro release of LH from perifused pituitaries of adult females treated with or
without dalargin.
11- In vitro release of LH from perifused pituitaries of adult females treated with or
without naloxone.
12- In vitro release of LH from perifused pituitaries adult males and females treated
with or without beta-endorphin and naloxone.
13- In vitro release of LH from perifused pituitaries of fetuses after beta-endorphin
pretreatment and later LHRH administration.
14- In vitro release of LH from perifused pituitaries of fetuses after dalargin
pretreatment and later LHRH administration.
15- In vitro release of LH from perifused pituitaries of fetuses after naloxone
pretreatment and later LHRH administration.
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16- In vitro release of LH from perifused pituitaries of piglets after beta-endorphin
pretreatment and later LHRH administration.
17- In vitro release of LH from perifused pituitaries of piglets after dalargin
pretreatment and later LHRH administration.
18- In vitro release of LH from perifused pituitaries of piglets after naloxone
pretreatment and later LHRH administration.
19- In vitro release of LH from perifused pituitaries of piglets after pretreatment with
different opioids and later LHRH administration.
20- In vitro secretion of GH from perifused pituitaries of fetuses with or without
naloxone treatment.
21- In vitro secretion of GH from perifused pituitaries of fetuses with or without beta-
endorphin treatment
22-In vitro secretion of GH from perifused pituitaries of fetuses with or without
dalargin teatment.
23- In vitro secretion of GH from perifused pituitaries of piglets with or without
naloxone treatment.
24- In vitro secretion of GH from perifused pituitaries of piglets with or without beta-
endorphin treatment.
25- In vitro secretion of GH from perifused pituitaries of piglets with or without
dalargin treatment.
26- In vitro secretion of GH from perifused pituitaries of adults with or without
naloxone treatment.
27- In vitro secretion of GH from perifused pituitaries of adults with or without
dalargin treatment.
28- In vitro secretion of GH from perifused pituitaries of adults with or without beta-
endorphin treatment.
29- In vitro secretion of GH from perifused pituitaries of adults with or without beta-
endorphin and naloxone treatment.     
30- In vitro secretion of GH from perifused pituitaries of adults after naloxone
pretreatment and later LHRH administration.
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31- In vitro secretion of GH from perifused pituitaries of adults after dalargin
pretreatment and later LHRH administration.
32- In vitro secretion of GH from perifused pituitaries of adults after beta-endorphin
pretreatment and later LHRH administration.
33- In vitro secretion of GH from perifused pituitaries of adults after beta-endorphin
and naloxone pretreatment and later LHRH administration.
34- In vitro secretion of GH from perifused pituitaries of adults after beta-endorphin
treatment and subsequent GHRH administration.
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9.0    LIST OF TABLES

1- The amino acid sequence for endogenous opioid and their derivatives (Friedemann,
1994 ; Martin-Schild et al., 1999; Reinscheid et al., 1995).

2- Some common selective synthetic exogenous and endogenous ligands for different
endogenous opioid receptors (Calo’s et al., 2000).

3- Number of experimental animals according to age and gender.

4- Number of animals for the different treatments.

5- Mean ± SEM of basal secretion of LH and GH before treatments.

6- Opioid-induced LH release from pituitaries of females and males in all age groups.

7- Opioid-induced GH release in both sexes of all age groups.
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10.0  LIST OF ABBREVIATIONS

a.a.  Amino acid
ACTH    Adrenocorticothyriod hormone.
Ala  Alanine
AP  Adenohypophysis
Arg  Arginine
Asn  Asparagine
Asp  Aspartic acid
BAM  Bovine Adrenal Medulla Peptide.
BIT  2(P-ethoxybenzyl)-1diethyl-5-isothiocyanatobenzinidazol.
CNS  Central Nervous System.
cDNA   complemetary Dioxiribonucleic acid.
cAMP     cyclic adenosine 3‘-5‘monophosphate.
CHAP    (3-chloamidopropyldimethylamonio-1-propanesulphate)
CPM       Counts per minutes
DAGO D-Ala2,N-Met-Phe4,Gly5-OL-Enkephalin.
DSLET Tyr-D-Ser-Gly-Phe-Leu-Thr-Enkephalin.
DPDPE D-Pen3-D-Pen5-Enkephalin
d         day
DHPG          dihydroxyphenolglycol
EM-1            Endomorphine-1
EM-2  Endomorphine-2
Fig        Figure
G-DAMME Guanyl-[D-Ala2, MePhe4-Met-enkephalin-(o)-ol, FK 33-824]
Gln      Glutamine
Glu       Glutamic acid
Gly      Glycine
g      Unit of  centifugal force
G-DAMME Guanyl-[  D-Ala2, MetPhe4-Met-enkephalin-(0)-ol, FK 33-824]
GnRH     Gonadotropic releasing hormone
GTP        Guanine Triphosphate
G-proteins     Guanine proteins
GH         Growth hormone
GHRH      Growth hormone releasing hormone.
5-HT       5-hydroxyhyptamine
5-HIAA   5-hydroxyindoleacetic acid
H-endorphin     Humoral endorphin
hrs      hours
125I      Isotopic Iodine for labelling.
icv       intracerebroventricular
iv        intra venus
im       intra muscular
ip        intra peritoneal
IGFs    Insulin-like-growth factors
LH       Luteinizing Hormone
LHRH    Luteinizing Hormone Releasing Hormone
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LPH        Lipotropic hormone or Lipotropin
Leu-Enkephalin        Leucine enkephalin
Lys        lysine
min       minutes
M       molar
MEM      Maximum Essential Medium
Met-enkephalin          Methionine enkephalin
mRNA    messenger Ribonucleic acid.
mm         millimeter
NaCl       Sodium Chloride
ORL-1     Opioid receptor like-1
PBS          Phosphate Buffer Saline
PCP          Phencyclidin
p.p       Post partum
p.c        post coitus
pGH     porcine Growth Hormone
Phe        Phenylalanine
POMC      proopiomelanocortin
PROENK     Proenkephalin
PRODYN     Prodynorphin
Pro          Proline
α    alpha
β     beta
δ       delta
ε        epsilon
γ        gamma
κ        kappa
µ        mu
σ sigma
ζ   Zeta
SRIH    Somatotrophic releasing inhibiting hormone or Somatostatin
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